var title_f14_46_15072="Muscle displacement";
var content_f14_46_15072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Muscle displacement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 372px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF0ATIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKw/DOtPrE2tK0aIlhqD2SFc/MFVSSffLH8q3KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDg/hFL59j4mmEnmJJ4hvyrY7CTH9K7eaXyxnBryv4W69pvhv4X6lrmuXaW9kuq3sk0m0kRlrllAAAJ6kfnXSeDfiB4e8dC6GgXqyTWjlZYHwsmOzgd1PY/yprVhI6aw1W0vr2+tLeTdcWTKk6kfdLKGH6Gr9ed+B2YfFT4gJu/dsunyBc9D5TA/wAhXolDVnYEFFFFIAooooAKKKKACiiigArzK8+Nvg+y1W/sr19Tgjsb17C5vGsZDbxTKxUhpACByK9Nr588P/B/VNe1TxtF4p1HVNO8P6h4invRpsBjCX8Xmb0dmGWAOBxx0HQ80Ae/LcQs21Zoy2QMBh1PIFMgvbWe4lgguoJJ4eJI0kDMn1A5H415DpXw3kuPHvxB1e801Le6meI6FfO2fKYW5QugB4w2Oo7Vy/w88E6taa/4DS28HT+H7/Q/O/trVnaLbehkI2qysWl3nnJHy54oA+hor60lmWGK6geZlLqiyAsVBwSB6Z70yDUrG4uHt4L22lnj+/Gkqsy/UA5FfO3w++FmqaHp3wtvv+Ef+ya7Y6hctq86MgkWFmkC7yG+YbSowM8H61T8M+CPFNx498M6vf8AhVtLuLXU5v7R+zWtpBbCJtw+WRG86YEEAl8jnjPNAHuUHj/R77wxe63oqXerQ2kxge3tUUTMwcI21ZGUYBOckgYBxmumuL21tpoori5gillOI0kkCs59getfLx+HWqQfC3xx4ZsvBM8PiKa53QXyLCI7m3+2ROsaSbsnCqWwQAAvrxXRfEnwZqV14q8eSXng2fxLLrtpDDod/GYiunssRUgl2Bi2uQ2V+936mgD3+5vrS1DG5uoIQuM+ZIFxnp19asV87ax8LNU1W98TSa9pKatdr4SgtLK7kKnzNQSEgsmTkNvxycdfrXtXw+tLzT/AXhqz1NHS/t9MtobhXbcyyLEoYE9zkHmgDfooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkdgiMx6AZpar6i4TT7pydoWJjn04NAHz9ohuE/Zfee10681EX09zLdR2zL5qxtcSbnAZSDgAcY/LFeZ3eraVYHRLrU9L1KLzI1W38T6OBaXII4xLgmKXHGTkE45xzXtXgDxJZeEf2bdE1fUUlmsI4Cs/wBnYB9rzMpK5xyN3TrXnFjrWjx3xm8H6hd3WlS7mmzbiUyA8YuLZsJOP9pdsg9D1oGdH4D8bS+GvFOs6v4gvjrun6lDbRvf2tv5c9uYwygy2/XBDcsm4cV9C6ZqNnqllHd6bdQ3VtIMrLC4ZT+I/lXyzLpmj6rpkl5p4j05YgXe50hWvbAPjJMtqcTWx4xlRxXPwXPibwK7a5oN60Fq8gd7u0c3mmXWRnEmPnjP++Mj1FK7Cx9oUV4l4D/aC0LVlhtPFkX9g6i65ErNvtZfdZB0+jdPWvaoZEmiSWF1kjcBldTkMD0IPemIfRRRQAUUUUAFFFFABRSE4GcH8KWgAooooAKKQZz7UtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVR10btE1BeebeQcf7pq9VPWiBo1+W6fZ5M/98mgDzX4YWTTfALQ7FIo5ZJdNOyOREdXYliF2t8pz714Dd+FdB1lL2eS0v8Awnfwy+XdTWUTTWsb4zie3z5kHI6ruT0r0/xBY3N1+zx4PsdPvGtNRZLaW2dZNkm9QWGz+83+zkZ7c8V47f8Aj/Xry/t5vEVxt1K2k8qHWYU8g5HGC6gFfdWBB7gVUhLqS3ukeNPDcMOrzwQeJdKgBMWtaLckyxLjj99H84xno4Iq/wCH/iFY30weS4V9Rf5WkaQabeA4xzKo8mf6SKCadF4jlsJYbrUdOa3vJPkTVdDnFhcTYPJO3NvNnIz0PFa98PD/AIrzbazDpWrag2f+PiL+xdWBJB4P+pmPX61BRpXOh6FfXZXUrZYrm4Rtj/Z0sLsrgcbTm2uO3KlSa3dK0Xxz4Pdr/wALyvf6IzfNb20BR4yBgh7Vzg+5iYe2a5/w7/bPhWE6D4bvLXVNLL+YfDfiu1W2mOW/5ZSnMb5xxhse1d54Q+KPhPw9fyafr+m6t4NvZsZtNQ3taq3rG3KgHjnAFAHSaH8WNKKRp4jltrHLrD9tictbNIf4TnDxN7OB9TXo8M0c8KSwSJLE4yrowII9Qe9eb6/8NfCfjOynu7L7LPDeZkLxsJI2Y/xKwOVP0OOeleSXXhX4ifCe+kufBd3PfaMp4sZz5kGOpyBjB9/lNAH1PRXjPgD4++H9eWO18RRtoWq8ho5smMkHGQ2OB9fzr2G2uIbqFZrWaOaJhlXjYMp/EUxEtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFAzzmiigAooooAKzPFGf+EZ1fb1+xzY/74NadRXcYmtZomGQ6MpB75GKAPD9WvNOsfgd4Uj1K5SMTW1rDCXYKjuV+62QVwRn73HqR1ry/UNM0XW5PLS6bQL+Jwjpegm1kz0DPy0XOCA+9PRsV6S09pqH7OkBuUgeGKw8sLdwmSNXjcr8wXkDjG4dOtePWs0rC2j0adZHtYv3WkahOI5oCxxi0uDw6Hsj/k3WtKnQUepBrXgfXvDyAOk+mLMeVdl+yTHOeH+aFumeSv0rMjudW0SxktdUhe7sZMSJlVZFOBnCOGQ/8BYGun0Tx3ceFLqXT7q/1TRJcYeCa1GASfmMls/7twf70ZU+1dno2oeHPEM84TTLOS6ILSXnhO6MEpAP8dnJgnpyAHrL1KPMtJ8aaXagRE3NiqjZNDbzExtnPW3n3xtg/wB1hXt/hrxhpeuaPbaFqttoGv2AVUS1eP7JOoPAxFKSjH/cf6VyVx8OvCevSm2sdV0u7umJf7HqcT6Ze5PH3gAGOT/zzNclrHwY1vRUmksDrOm4ckRTQ/a4CuTg+ZDn9UHWi3YPU9fHwejt5JdR+F2v6z4SvgcvZTh2tySOhRv5/MK53UPEnxA8EXcsnjLQrsozZbWvD+Hjk/2poD8jfiENed6D4r+J3g6MW+kalFqVvbsWMSv9pjKDjbg8qP8Avk8GvYfBP7RWmXEMdv47sJtDvGOBPGjS27j1yMlee3P1o9QOV1HWPAfxDWOO6+zm5zvNzp8flupHHz2rkNnuTGTVHQtH8U+CkfUvCurrq+ihv3s+nzbniGf44mHJx2df+BV67rPgL4Z/FG2N7aLp81y4yL3S5lSUHrk7ep/3ga8/n+C/jrwZqkGreBPEUOqG1bfHbX4McjLjlCwOGB9CQKN9g2O98J/FRruNVvoBqAGS0lhGVnjUDkyWzHd9TGXFejaHruma7bmbSb2G5VTh1Q/NGfRlPKn2IFfM+peLdFl1NY/iT4U1HwRr4J8vVbGNjCXJ+/xyPqpJ960bs65awW2t77LxfpsJBTW9HuBFf2wwRlnX7/8AuyA89TQB9NZorw7wl8WbpZja3Uqa0qhcQsq2mop8ucGNj5cx/wBxgfavUvDfi7RvEW6PT7sC8QZls51MVxF7NG2GH16UXCxv0UUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFV9RleDT7qWPZvjiZl3ttXIBIyT0HvQB4JoFvf3nwzt7jwysS6tY393JaJJ9yVPtEgeI9iGXI54/nXizS6fqmqz2ohXSNTadozpd2NggPUhXxhV9iCv0619J+A9Mfw/wCBtF0+YxtPFBvlaNgyl3YudrdxlutY/wAQPAuh+NrMjUoBDfg/ur6BQJUPue49jXY6HOrrcx9pys8gsrzUdGmXSvGMUl/pb5NqdSsBd22Mj7hB3ge8TEe1SH4e+FPEp+06bb6ho0ij5rnR5Df26Nzy0JxPF06EGq95eeNPhE1vpEqW+s6FcSsbZHjE0cxGCd0R6EdeMfWvQtL+JPgDx0sZ8T6YunauqgLf6cWWWM9gCmJFI54ww965JJwdnobp3V0cZH4J+IX2dE0DxPoXjKyjY4tbiZJnTHT5JhlT04Bqex8UeNfCMf8AxPfCvinSI1YN52lzu8KgY48qQSJjrwCPSvTWs47lF/sXW7HxBZRAbW1qyW4dR1I86LEqHj+JTzXX+GPGj/YFSTRt9pEoCzaXeLer9NpIkHXoVNToF2eRD4peE/ErRrrc+kXU6AYOq2b6fcg9ys8e5V6n0rq4vh/4d8VaZHP4Z8Q2sjldywTyRXgjJ7b1Ikxx3Y16jr3hDw94jtS2o6Jpl1I6ZSS5tFYqccZyAfwyK8O8T/s7LdzZ0K40fSL0DcjW7zoSc/e2lmx+FP0EZWrfBHxDpOoSXmm6PbXjqQ0U2laibKZD3I3DqfTn61Vm8d/ELwtYyWt9rGo6bMHHlJ4j00uOOSouowVbPT5gOvUVo23gT46+Fg0ej+ILfVrQrgwz3QlDDuMSjj8DWlZ/EX4p+GreCw8RfDP7daqmM2KsQR/wHePwpb7oaMqX4ueJmtm/4S3QlubKRQv27SFS9tHHYPExKn8GU1zdtP4E16Sa50ieXw9qjHDzaISqOM/8tLOQg4HUhCwq3rHiXwPqOoT3l7oXjHwZqu7c0thbKqqwPsFPUdxVG8n8H6/GwuPGegao0uFP9vaTJZ3MWBgfv4RyfUnI70AZeveFvEc8U0mm/YPEkaYZp9OH75QM8yW7YkU9eQCK5/w7431Kykji1m2/tS1gK7I7kuZrcg8KkqkSxY7dR7V1zeBpZkaTwt4gtpp48FIrbWIbpR9CxSRR7c1yuvxeIotSFx4u0C/uEUbIrtIWfocEhxyenHzHFG4I9R8EfHi50+Vbaa8bUbUbV+zarIsdwpzz5dwBskAH98KenNe/+EfH/h/xVsj0+88m9I3GyuR5cw+in7w91JHvXwRPcaTfySRbbqzuCxAEqiUPz0zwwz7g1q6fpt9BdwWkO+a2yCokDMqHjo3DIRkD5cfjS22HufodRXzf4U8ZeP8Awhb6fa6zZXOopcSFI7bUQyuwx8oiuvusT2WQA9ga9V8PfFHw7qlytjfvc6Dq3Q2OrxG2kz/slvlb8DTv3FY7uikUhgCpBB5BHelpiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuO+MSu/wAKvFixnDHTZ/8A0A5rsayPGOnHV/CWtacqlmu7KaAAdyyED+dAHA+HZMeEtDCACP7DAV/79invLyOw7CsD4aX4vvhp4dlHDx2qwOCc7Wj+Qg/itbjNyvXg/ga9entc457nJ/Ei+TSZ/CustLGsmmatDLIpbBET5jdsenzCvRvGnwq8G+NF83VNJhS6b5lvLT9zN9dy/e/HNcZ4v8LaZ4u0trDWI32gExzRNteMnrg+nseKpx6t498FaSX0+/svEulWMIAs7yLybkRKP4ZF4Y4/vDnFc+JpSk+aJrSmlozK1/8AZ01OC4a68J+L7kSKuI4tRUuRgHAEq8jGeOOK4C98EfGHw3MFutJg8RW0bhwxVLksfXPEo/MV9J+Cvih4f8TeE7nW5JxposQPt8F021rViOM+oP8ACR1+vFRW3xb8L3FuLqN9QNiXKfalsZWiBHXJAOPxrhSv0Nz5qX4neJNImT+1/D/iXSFVvn+w3s8S59kmV1/D2q7ffGvT71ITcan4hSZUKOLzTbS5yPTcNhr660nU9P1vT47zTLqC9s5PuyRMHU+o+vtSXOj6Zd4+1adZzf8AXSBW/mKVkFz46b4taMqFVvGlXk4/sx4T14wUuBiqcXxw+wTEQ21/dwHjamq3UGPfBdq+wbjwZ4YuEKTeHdHdSMYNlH/hWfL8M/BEo+fwpop4xxaIOPwFFkFz5vtvipNqUUNzbeF/FpDIfng16R1b6BlNZOq69daoSYPA2uzzjvd6gsqjPfBi/WvqI/C3wOV2/wDCLaUBnPywAfypG+FngZj83hfTP+/VFkB8ew6J4juriYW/haPT0JDAyx28h+mX2/pW8ND8Sf2eT9gYT7QSvl28EYx6GOcfnivqNfhV4FVsjwrpRP8AtQA/zqJ/hF4AebzW8J6WXzn/AFXH5ZxRZBc+MDfX9xNcJd6NBdGAlZJDcrKMd8bi355ruvCml+C7+RoNcubnRYZIwBLYXzfI/UllIKntwBX04Phb4FHTwno3/gKv+FKPhf4GAA/4RPRsf9eq/wCFFgucz8PdW0TS59RjufiBb63pjLGlv/aWoxmSMqPmBUhfbnJ6VtXOr/D/AFLSF0rWvEOg6xBlv+P+9hlY5JPXPbOAR2ArUg+HXgy3IMXhXRFI7/Yoz/MU6b4e+DZjmXwrobcYz9hi6f8AfNFgOQsfh/YQwvL8NfGl/pCE5WCC6W+tAc/883Jx+BFXTqvxK0Bf+JloWleJbZAMz6ZcfZpz65ik+Un2BqTUPgp8P71mf/hHYbWUnO+zlkgIPsEYD9Kpj4QLYlj4e8aeLtKXHyxLf+dED67XB/nSAs2/xi8OxMIvEdtrHhu4P8Gq2EkY/BwCv6122i69pGuRGXRtTsr+MdTbTrJj64PFcC3hn4nWKBLTxrpGsREYMeq6UEGPrEcn8a4zWvC2t+abjXPhTot9Kh3fbPDWpGzl/wB4L8rMfbNGoH0JRXzhF4pj0a58mHxl4s8JTKcLZ+KtP+1QN04EmMhffdXe6F4u8ZzQ+bb2PhrxZZjANzompCN8dyUkyM+26i47HqWaK4H/AIWjo9m6R+JbLV/DsjkKp1KzZY2b0EibkP1yK6/SdY03WIfO0nULS9iwDut5lkH6GmIv0UUUAFFFFABRRRQAUUV5rffEeLwz8Tm8LeK3S3s9RRbjSr9vlQ5+VoZD2IYHB9CAe1AHpRooooAKKKKACiikYZUj1FAHy18HPEDmTUtJvgIYL68ub7Six4kj81hIg91Izj0NenA7eT1zzXn3gbQ7LV/h5Z6ZqkB+06Pf3EbMjbJbeZJmOQw5BwR9a9CDby5B4UZJNexSVoI45vUeWKjDYyeRjtUNxcRWljeXFwVEEMLySZ6bQDUNhf2t6ry2d1HcIjGMtG24AjqM/wCFUfFttYXHh68/tm5e304bZLnacGVFOfL/AOBEAcc1o9CVueNajb3MfjLwfooZ2bWrKxk1GIDqsUjOu4eygflXuWmaVb6Pq2p3dgiQJe7GaCNQqBlBBYAdzxn6V5f8LreTXPE+r/EnXo1s7KRDDYRSHAiiAC78noABj3JNesW0kssatKiRyHONrbhjtz9MVjSjvLuXN9DJZtX8IalPrPhG0iu7W5O/UdIL+X5z/wDPWE9Fkx1HRvrXZeHfit4V1hvJnvjpN+uBJZ6ov2aRG9Mt8rdexNZAyr9iOxqG9tbXUYfKv7WC4hzws0YfB/Gs6uGjN8y0ZUarWjPV4pY5U3RSK6+qnIp9eHp4Y0y0Eh0z7XpUjkEvp9y8JJx6A4/Sr9nc+L9KjgSw8SJfQp1TVbYOzD0MiFTn3Oa55YSa21NFViz2GivL1+IPiHTiTq/hlb2AH/W6Tch3x/1yfB/I1p2HxY8K3EqQX91c6Rctn91qdu9vjHqxG39awlTnHdGiknszvaKqafqdhqUYk069trqMjIaCVXH6GrdQMKKKKADHNFFFABRRRQAUUUUARXNvDcwtFcxRzRMMMkihlI9wa4fV/hJ4N1C5N1DpI0y+6i60uVrSRT6/IQPzFd7RQB5j/wAIh460MyDw54yj1W0I+Wz8RW/nH6ecmGP4g1yur6UsNz9o8U/CueOeMgrqXhW43MT/AHtiFH688g17xRQB4To/iBVmMHhv4myW9wrgHTfFdr86/wCxvYI+e3Bau0/4SnxlpSI2teEE1OA4zc6FdCXI7nypNrfkTXaarpGnaxb+Rq1ha3sP9y4hWQfkRXHP8KtDtm3+HLvV/Dsm4uf7MvnRGPvG25SPbApWAfZ/FnwhLeJZ3+oS6ResP9RqtvJake2XAX9a7Owv7TUIFnsLqC6hbpJBIHU/iOK4DUPD/ji3hMUeqaH4msQuDbazZeU7D03x5Uk+pWvNfEem6BoEE+p+Lvh5q3hbyyobVPDd8GjXJwDhGXaMkdVoHofRGqahaaVp9xf6lcxW1nAheWaVtqoo7k1w2hfFrw/quvW2mSW+q6ab3P8AZ9zqNoYIb7H/ADyY9c5GAcZzXgvj1fDfizQrOLTPirqt5ZifK2eryFQGOQrl2VchWwOQcAnpXteny+Gvir4PPhrWmZ9TtIUFzGzAT286jb5qMBgkHJ3Dg59DimI9Sr54/bS0SO68CaTrAUefY3vlZ77JFOR+arXc+G9a1/wZqmk+GPG8qala3rm207XUO0yOBlYp0PSQgHDAndj1ya7nxFoOneIrOG01i2W5top47gRt90uhyuR3Ge1AHzv+yl4r8d6xbtZTvaal4csXEEkl1Pi5tsjIC9Sy+gb04PGK+nR1r570OL/hB/2qr7TLYeVpniiy+1LEOFEoBYkD/eST/vuvoQUgCiiimAUUUUAeV+Lfh3q0HiC91/wHe2lvc33z32m3wY21zJ/z0BXlHxwccHvXG6t8Pfif4wtJ7PU73RPDunscNDbO8zzj0ZhjCn2IPtX0NRWirTS5U9CXFN3aPE9O+HXj60t47KDxB4bsrBEEaC201i0Yx1UFsE/Wt6z+EVk0V3Lrus6lrOpzW8tvFc3JUJa71Klool+UNzwTmvTqKJVZyVmwUEtUj5pfwF4/8LWVnY3Wn2/i7RbFVFvb2c62xG3ODIjDLkcHGSPrXR6enxE1mMSWnhGz0lT0Oq33P/fEYJ/Ovc6KtYiola4nTi9bHiL6d8TLCImfw5oOpkEn/QtQMJx24kXr+NUf+Ei8RWj7NY+H3iO3JP37RUu0A9coeK98oprFVEJ0ongKePPDq3Ahv7uXS7jPEWpWz27fmwx6966VJY7m3MttLHJC3SSNgyn8RXqN7ZWt/btBfW0NzAww0cyB1I9wa871f4L+F7maW40VtQ8PXUnJfSrkxKT7xnK/kBW0cZ/MiHR7FMvg/LwemRSy7ZkeOZVkixgqyhhj6Gsi88H/ABH0N1Nhe6R4os0GPLuU+x3J/wCBDKE/WsufxPqNi3leKPB3iHTCAS88MP2qBcdfnjzx+FbxxFOXWxm6ckaD+F9Akk3xaXBbynJ823BhYe+UIpw0nVLcOdH8X69YEYAWSYXMY/4DID/Oqmk+N/C+puEtNatFkxgRzt5Tfk+K6NGEkWUkWSM91OQfyq3CEt1cXNJGXF4h+JelgCO58PeIIx2nje0lP0Kkrn8KtJ8XdcsRjXvh/qykHl9Nnjulx6/wn8KtbWwWBzinCQsoO7AHXFYvC03sWqshbf47+DshdTGsaTIRnZfadKp9/uhhXQ6d8U/AuoqptvFWk/N0Ek4jP4hsEVz8VwzLtbB46EZNUrnQtGvFYXuj6dMzff3W6En6nFZPCLoy1W8j1Kw1nS9RiMthqVldRjq8M6uB+INXwcjI6V4TefDvwfdqEfQbSNfWANCT9dhGaqx/DLSrdmOi634l0hzyBZ6k+1T9Dn0rJ4aS2Y1VR9AUV4UuheOrFE/sj4mXhQ/w6jYRXB/7661ZttQ+L9koQXvhLVQDnzJ4ZYXb2wuAKzdGa6FqcX1PbKK8gi8dfEe0cm/8CWF9GB10/VFU5+jirsXxWvoWUar4A8U2w4LNBFHcKP8Avlqnkkt0PmXc9SorzaH40+DvNePUbjUNLkTqL/T5ovwztIrdsPiR4Lv1zbeKdGPs92iH8mINJprcZ1lFZFr4n0G6LC11vS5ivB8u7jbH5Grn9p2B24vbX5uF/erz+tIC3XkF9a2fxf15zcSPN4I0W4KLCvCaldrnLFv4okzgY6nPapr/AMQan8R9ZvdE8LytY+FLORrfU9YHD3LDhoLc9h2Z/wAvfvtHsLPSdMttO0u3jt7K2QJDDGMKqj/P41UV1E2NutA0a80YaZc6PYy6aI/KFuYF8tVxjAGOPwryj4n+D18CnTPG/gezaKTRxHFdWUZO2a3A25PfhTgn0we1e1RqWVQcYz0rn/iD4o0bwp4cnm10idbgG3hsUG6W8dhgRInUk5xQ2JHFfGnV9M8Q/Aa88QWswURrDe2cmQHiuFkXaP8AeByp/GvU9GuXvdHsbqQESTwRysCMYLKCePxrxL4Q/Bh7bT7PUfHEtzM6zfa7bQWm3Wto38JdekkgGOen1r3h2CKWchVUZJJwAKko8B+Jv7/9qP4cQwczR2zyPjqF/enn8jXv4r52+E0rfET49eJfHKAto2lR/wBnae5HDkjGR/wHex/66CvomkAUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigDJ1rw1omuxlNZ0iwvgQRm4gVyAfQkZFcLf/AAP8HyzmfS11PRJyc7tMvXiH4KcqPwFeoUU02thNXPIZfhLrltKW0j4gaoka8JFf2sdzx6FvlJqjceC/ifZyFrTWPC+oxDny7i2kgJ/75zXtlFaKtUXUnkj2PnuaT4raZlrvwLp2oKDw1hfqD+THP6Vm3fxN1DSRnxH4C8S6av8AFKIDIn54Ar6WoqliJ9w9nE+b7D40eCroBZ9QuLKQfKUubZhj67ciur0rxl4U1EH7L4i0qVjyAblUYfgcV6dq3hrQtYRk1XRtOvA3J8+2R8/mK4rVvgX8OtTkeSTw3BA7DBNtI8QHuFU4H5VX1mXYn2SJrae2uRm2ubaZAescqsP0NXliduUOcjPy8/rXEz/sz+BGVvssms2jHoYrwcfmprHl/ZrNrMG0Lx3rtggPCsN5H4qy/wAqf1jyD2Z6h5b7CPzxViEShuF4x1715qvwR8VqFUfFbXAgGAPJbP8A6MqRPgl4nGc/FbxDz6IR/wC1KXt12D2Z6Wd8mUkTdgdGGR+tZ9x4a0O9k3X+iaZcMFPzS2kbH+VcMfgj4k5KfFXxIG7ZBI/9GVNb/Cvx9Yy77L4q3sgHRbmwWRT9QXNJ1Ux8h0lx4A8HXSkTeFdHfByCLVU/UAVA/wAL/Arywy/8IxYrNC4dCm5cEHg4B5/Gq0Ph/wCKtlGRH4g8LakRz/pVjJCW9iUP9K6nwTD4omguv+E0tNJtp1cCH+zZXdXXHJbcOOalzQcrNDTbC10u0aKzgis7RGeVlXhAWJZm9uSTXGzeObzXJJbL4baYutuGZZNTncxafC4PTdjMh9k/OtfXfhtY694he/1bVtYuNNYqx0f7TttGZRjLKBkjvjOM12djZ22n2kVrY28VtaxLtjiiQIiD0AHAqHK5SR5VL8O/HOsyNL4g+JV9ah+fsujWy28cY9FcncR7nmt7wp8KvD3h/V01idr/AFrXEGF1HVrg3EqcY+XPC/gM89a76ioKCvM/j7F4uvvBi6R4IsjPPqcwtbqdZApt4W4J+h6E9hn8PTKKLAct8NPB1n4E8G2GhWOH8ld002MGaU8s5+p6egAHauppCM9R0pRR1AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEbOPlxn3pRQevWjvSAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACHOKAOc0tApAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAyKBSMM49jmlFIAooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIcgjA780ClNApAFFFFMArD8c6pc6J4P1jVLFEe6tLZ5o1cZUkDPNblcr8VGK/DfxKw7WEv/oJoA6W3kMltFIRy6BsD3FRTXJj3k4wgJP0xRYn/iXWx6ful/lWdqhb7BeEE7vJk5/4CaqKuTJ2MX4O6td698PtO1e/uGnnvZJ5tzdl85wq/goA/Cu1rzX9m8k/BPwvkYPlS/8Ao6SvSqkoKKKKACiiigAooooAKKKKACiuO+K/jeP4f+En1mSzN4xnjt449/loGc8M7YO1Rg5OD2HesXw78Q7lNH1LWvFkvh0aBZxLIdU0O/e9jDFguxkCbweR0BoA9LormtR8c+HdOur62vdR8uex0/8AtS4XyJDsts48zIXB5/hGW9qyIPij4a1Nb+DSdRK3sOnPqMJvLOeKOSJVz5i5QF1HGduTjOM0Ad5RXnR+LPhnTNF0ibX9VjN9facuoKtlZ3DpLGeC6DZuAznhsEDk1o6h8TfDNnpGm6mLm8urLUIWuYJLOxmnHlrwzNtQ7ACcHdg/kaAO0orzDxB8ZvD2k6z4Shh8y90rX4Jrn7fDHK3koi/IRGsZZyzAqVGCmMkVo2fxG0q2sPEeoa5qtgtjpmpGxU28E4dTgbY2Vly8nP8AACPyNAHfUVxEXxU8INoWoatLqclva6dLHBeLPazJLbu5wgeIrvGexxjrzwa0fB3jrw/4wn1CDQb1557BlW4ikgkhdN2Sp2uoJBwcGgDpqKKKACiigDFABRRRQAUUUUAFFFAoAKKKKAA57UUUg70gFooopgFcT8bLn7J8KPE82Cf9DZOP9ohf6121ec/tDyGL4N+JCvUxxr+cqCgDq73UrTRvD0V7qcwgtIoU8yZgcLnAyce5qBJbfU9Ne4064huraaNlWWFw6sCCOCKwvijFYyfD2VtRtY7xUSPy4pFmKlzgD/VfOOvUdK+XP7Qfwtrck3hHVLnRJSceX55uYWcnoysqyY9mRvrVxlykuN0fTX7OqhPg34ei5DRrNGwPUMJ5ARXpFfMfwQ+MmmeGtNt/C3jJDZzfaJWj1KMhrZzI5f5iPucsfb1xX0va3EN3bx3FrNHPBINySRsGVh6gjg1Fy2S0UUUCCiiigAooooAKKKKAOc8eaXq2r6CbXQ5dLE5kVpIdUtvPtriMA5jdeoBODkc/LXlVr8DLmXSfGC3FzpGlXWvWkdrHZ6RA6WkBRw4chjliSoHAGATjOa94ooA8F8Q/D7xYujeL9b1u6sNS1O68MPpMVnpNrKCWU5XAJJYn2A5PA4q3oPw48Sa7a6Vf+J7zT7b7F4dk0vT7W3gkV42mgCM8+/ncBwVHcdu/t9FAHlfhn4Y3mj6x4fvJNQt5F0zw2dDdVRgXctnePb261zw+DmvxaB4V0hNZ066sNLtJra4tLpZxAzvIzidVjdSzAEDaxxwfWvdaKAPFrX4V+IdF0j4eNoWp6VJq/hMXif6ZHJ5E4uBgn5fmBA/z6zX3wl1Key1iWHVbSPVZfEqeJbF2hZoklQYEci5yVPPQ+lex0UAeKav8Jdd8Q2Pim71vVdNTXddnsmYWkTi3gitmBAG47mZh1Jru9C8JT6b8SfE/iZ7mJ4NXgtYUhCkNGYlIJJ6HOa7CigAooooAKKKKACiiigAooooAKKKKACiiigANIO9KaKQBRRRTAK86/aGjEnwc8Rq3Ty4j+UyV6LXAfHpQ/wAIvEgJx+5QjnHPmJihAee/tGeLb3SdO0fQV0T7TZXojl+2TEmF2UHMRC4bd0PBB54rxi/1/Sru0jtrs3+jwp0juR/alhnHQE/vYSSOxJFen/tNeIItMgtbR7O7lMtihabzVe3Y5ysckR+63UhwQ3pnmvJbfxFbTWFvc+I9Gur7TmRUTVIHWO5t2HbzANsvGRtlGfenLcFsWJ4dMuIovt0dm1oePtSyG8syf4QHX99CPXeGHtXf+BfC/ivw3qJufh5rcSxzR7otOvX86yvj1YRSISgI7E7W9QK4bTdA0y/U3HhuaPUZipJFiPs95HzjL2rHEn1ib8K6r4c2us6Zq80vgy8e4vIxmWzWTyZSemJYnABxzwwU+j1JR7V8P/jDofia9OjayP7D8TW7FJrG5cBWccHy36N9Ov1616jXx74riTxnqV7Dr2gquvRMzPJEjwSEAclojmRCP7y709u9dT8PvH2veH4Us7S9fxTptvColt7g7bm2A7+Zz8uO5yvuvSgVj6ZornvCPjHRfFcMjaRdbp4QPOtpBslhJ/vKf5jIPY10NMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIeoOaWmsAWGR05FOpAFFFFMArhfjkN3wq8QL8uTHGBu6f61K7quL+M6b/hb4jGzfi1Jxj0YH+maAPmL9o/xBcQfEt5tMeM/ZbVLC+tpolZGH3hvH8SMGBHcHPSvKrK9iF2JvD92+lXUgw9vK+YpCewJ42+z/AJ11vxxWLUviPqOqwyJBA8i28rI28I6qFDn1U4GfQ5FcldeGbtreWeO3SWEAO3ksPMAxyyrnLJ3yMj6U5bgtjptLex1mMpqOnHRtSVcefp64R9v8RiJxz13KVr0rw5qU8j2lv4usp9etIxmC/tGb7ZbANncjDE2B7F1rxTR7/UtFkTyQt/ZQsHNuxb92fX5SHQ+6mvevBNvoHiq1t1uZUsVnJVrxpANshGR+8A8qQ9OGCSD3qSj2TQdO8L+MNDFpd6tH4ma3djFPcbUvLYehKhXVh64B9a4Tx/8ABLUZ7g6p4b1WWbUIgfKklk8m6QAcKJV4k9MOM4/irX/4Vlr+nyi4gvrLWWt1Jh+1l4Zz83RLhPnTjHBLg10fh/4i6bDF/Z2vJfaPfQMYA+qkeXM444nX5Dk+uD7U/UR87y6zd6LqMVl4yt5vD+sWaj7PqFhF5eWPILqOVz3ZNyHupr2jwn8WZ4HtbPxXClwk4H2fUtOImWUd2ZUz07lc+4WvSdT0XTPFWixweINOs7uKRdxjYiQKT3V+D+IxXiesfAvUfDklxc/D7UQ9o4Jk0u8PEnOcZ6NwSBnaR/epWC59AWN5bX9slzY3EVxbuMrJE4ZT+IqevkGy8V6x4G1RYSt74b1GSXc9jfx/6JOOmVkPBP1Of9s17X4G+Meka1dQaXrmNM1h03DeCsEvurHp+PHoTRcLHqdFIrBlDKQVIyCO9LTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAYFFFFIAooopgFc38SgD8PPEu7oNOnb8oya6SuP+MN5FY/C7xRNcEiP7BLHx1y67B+rChbgfL/AMTFj0XxbHf6tpaz+HdftoLqGSP5nik8pQ52jqD/ABL34IORWJZWsmlNFdeFF/t3w/G/2ibTpZCJbP1ZHGGUeki9OjjNfQvifwPpHirwhpui6mjpJa2sS2t2n+tiZUABz3HHI71856t4e8WeDdRbX7Bh9ktpGCXViGMTOpKtux8yE4Oc8H3repSa95ERmtmeheEtJ8N+NZEeGL7VeJ801i8i2WqrnnKniOdcfxja3rXUP8MNX8K3Q1bwtFd3uny7GkgUrDeqo6rJGR5U/wCIDeh71w3grxr4K1KxtIPiNoDabPO4ltdcstyIrj+IFDmJs9Qvy56gV7l4cPiywtLa68Pa9YeNvDzruT7S4juwpPG2Zfkc4/vgH3rnNDY8IfETQdXNrptxqUVtrrKA1hdQtaTbueBG/fA7E1oeOY/D11pwtPE7iC1c71mYlFRumd/QH61X1DQtD+IOjr/wkXh+aOSJ8Kt3H5c8LDnKOpyPYqcGsRPDnjXwzCYdB1m38R6Uq4FhrnEwXP3VuFHPHHzqaYjEs/hzrugTR3Xw/wDFLLp8rbvJlIkjIJ67fuN9RtPvV3xN4m8b6NYGLVtA+0RdG1DSQ8sbLznfECJY+P4l3Cuak8ZxaDqEser+GNa8EzudwuLYrLayN1II/wBU2fXg/SumsPiTqcAgknsYNc0+b7s2mt5VyMnobdz8xx/cY/SkM5nSvidouuW8mk60bPVopvuWOpGMM4/upIQFZunyuEb3qlq3wp8MeJ1ktPCerTaPfRLubQ9Ry6R7ucBSdyA+qMV+tdRqTfCf4m3kljq0NmmtMMGO6jayvFOPfaTj8RXK638I9YsibPwX4tg1GG2J8rStcO94W/6ZSD5kx6jFHoI4i11j4r/BW/livrRtW0FMEx+YZ4VXPBVh80f4jHsa9s+Gvxz8K+NpEs3lOk6sR/x63jABz/sP0b6cH2ry1/EPijSNTtdJ8eaRJAjsI47jUJz5agA4Md6nzLk9pNw9TWF418JaJqksMtxb/Y3lx5ckxS3dxjP7u5TNvMc/3tpPrQM+xqK+OvCHiXx/4LnW10HVH8QRbVP9j6iGS5QeioxywwOsbEV7H8Pvj34e8S339l6zDNoOrqSrRXfEZI6/Ocbf+BAUXCx7FRTY3WSNXjZXRhlWU5BHqDTqYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAPpRQaKACiiigArzn9on/kjPiY4ziKMkf8AbZK9Grmfibow8Q/D3xDpeCWuLKVUAOPnC5X/AMeAoAx/Mzb2zr08tMfkK5Lw1Zz6JcaxYXEgawmujPYpIwJw43SIB3wxJ/GpvAmr/wBseBdAvy7sZLSMSEgZLqNrZ/EGrOoWdneXVndT26yXNoWaCQ9YywwcfUV60Fojkeh5l8Q/Cnh861Z3en3cOkL5wi1hbWNZAscn3ZXhJxsDYycdDVDW/hr448AXrat4RadELb/N0JmeJ1HTzLZiT0z90sPavSvEnhvR/ESFdWtFeTbt82NjHIFPUbl5x7dKyUh174cael/4U1O/1XSLP5rjRdQlEgaHv5LkZRgOQOQf0rnxGHbfNE1p1ejOQ8PfHDxTcbdO1a5t49Zh+XZKgs5HOcYKuDGx9soa9J0z4tazbKket6NbNMWCBHl+wzPzglVlzG/P92Q13t5oXhT4jeH7K+1HS7PUrO7hSaKSRBvCsMgBhyCM9AetcNL8HrPTppLfwV4qutMQgltJuyl/aH6wycgfjmuCxudEnxX8KvKLHxJ9p0KeYYEOsWxiSQH+6/KMPfNQ6t8MPCniCD7b4em/suSUbxPpUi+TJk5y0fMbfl+NcDqXg7xpokXktoVvqVgMlhod0qRkHAINpcBk6f3cV5vfPZ+HtUNws2qeD9RkVm+W2m03J7DaPMibv02jigD1Xxz4D186fCmqWemeJNMtP+WybYZo0AOSUfIzjGNjrXCTw263cNtpOq6npsRyGs9TX7RGGHaMSEFecj5JCaxB8RdaS7S5HiXT7u5kjMKTSgxSsOwZoTg/8CWobb4jeKJYTYXej6JrlrI5LCzlVJWPfdt4Jx6pQB1Eura/ev8AZL2C4u/JXaz2NwZ5Qnr5MpEuMnnDMK5tb3UbPzrHTorWYHPn20cn2C4YHPD20o8uTAHZSfeqF/r+iNAYZtN1jQWC8RywF4xID2IBGB7IDWfe+OrqDEaala6np6gbbaVUuAO3CTA7cZ6DGaLAS3WtLpd8LTxBp+p2EMZ82NHi8sRtnhljbKcDn5GTNbGnxr4tl8qPUNB8RwCEslvqtwbK+HJ+VJjz0J6s61z1l43iuoJ7SNbewuGjwFF1JDAGGeGik3xnPpwKqL4f1S7jF3N4Sa4jxva80GRZFPuY13L+GFoA9E8Naz4m+HlxHp+jX93aXGVxoPiRwscvPK283+rYehBUnPQ17f4P+MWi6vqaaN4gtrnw14gbj7FqI2rIf+mcn3WB7dM9q+PP7e1PSrSS0tdaMtkh+bSNZt+PU4R9yD8CDVyHx/A9l9h1PT4/swH/AB5S/wClWp7/ACBj5kJ90b8KAP0EByAQcg0tfGvwz+Jl7psvk+F9eSNAf+QBr85aFhnhbe5P3TjoHwPrX0J4R+LGj6xqh0XXLe48OeIlGTYajhd/oY5PuuD2xyfSi4j0aiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFAoAKKKKACs7xHqMWkeH9T1G5bbDaW0k7n2VST/ACrRrgvjzHNL8HvFi224yfYmYheu0EFv/HQaAPI/gQuraf4LhstWtNlrOPt1nOpyrJKclG9CDz9Gr0B2AbaOo7iq+iywzeHtKmtiPszWsTIFOBt2DGKlmI2Fiyoo+YseAB65r2aceVJHHJ3Yok3EEsFbHpzVi2ZZBtlQOpIGMZx7muVsvFVpqd4kOiWl3qcBfa13BHtt05wTvbAbH+zmrfjLWDoGhXD2wM2qXR+zafbry807cKqjvycmrlJJXJSdzn/CniC+T4N2eg6NMLW91LWbvT7WWPK+XbLIzySKR0wpK57Eiq6/Bvw89qssM9/Y65t3fb7e8kLCTuRuPPP0qzoGhN4Z1y3sJp/Oi8NaGlvMdw2/bLiQzS4z7bR9CK7dpSgUlTlucH1rlw9KMo3a3Nqk2nZFPwx468YaBp62Xi3QpddMB2JqWlyIXmQdGeJiMNjqQa3D8XvA1wht9buZdOctta31Sykj598qV/WqiOQrYODnoaRts0ZSaJJUIxiQBgfbBpSwcX8LsCrPqV7rwP8AB7xmzG3g8PzTsdxbT7lYn574Rh+orm9T/Ze8Mu/m6LquoWbHkLOqXCdPcA/rVzVvBPhjVogt/oWns46GOIRsP+BLg1l2/wAPDp0mfDPirxFoikg+VDdmSMY7BW/rWMsJNbO5arLqVv8AhRfijRmkOjajpl3GR9zz7i0P5KzLVXU/A/jq0uoJ/wDhFbW+kTaVkFxa3WwjufNjVjyB3rpIrz4p6QmbHxHo2uRDpHqVp5MhA7bk7n1NaNr8U/GGmsF8T+A5ZY1Hzz6RdLN+UZ5/WsZUKkd4lqcX1PIPE2j+JjdStrXwcsdQMh3PcWts8LtnqcwuQD+Fc5cWuj6RKk8vw/8AG/hq6XnzrG9c/q8f9a+m9P8Ajl4InlEOoXl5o85ONmpWkkP64I/Wu10TxVoGuxh9G1rTr5ScfuLhXOfoDmsnpuUnc+NH8d2bWawS+JNTu4oySLXxHokV6APTzA24cVCNb8BagJBqPhzw5Ju+VH065urCQe+1wyV9xT2FncbvPtbeTcMHfGDkfiKxbnwL4Tuf+Pjwzor/AFso/wDCiwHw/faB8NLu5CWfifVdGZsHbeWq3cY9cSRHJ/EV6d4d8O/atKGnWfi3wp4/0ZQoi0vVJ2trmL08hyd0bdsZx7V7lqPwX+Hl+ZDN4WsY2fq0G6LH02kAVx2q/sxeBbsq1lJqunsP+eVwHB/76B/nSAs+GNO8beFI518NfbtTsIcb9C1+QefGO/2e6UlGXsAfTtXVeHPitoOo6gNK1pbnw7rg4NhqqeST/uP9xx6YPPpWF4L+GfirwHFdR+HfGf8AaFtKFK2er2zOikdMMr5XjjgfhWzqWra35Bg8Y+A01Gz2DzJtOkjvE9/3ThX9+AaAPRAQwBUgg8gilrx/TF0OO42+BvGc+gTAA/2TqALQcg4Ahmwy8nnYRXRJ4k8X6NhPEHhcapAMf6doUocMPUwuQ4OOeC1FwO+ork9F+IfhfV5zbQ6rFb3o+9a3qtbTKfTZIAT+Ga6sEEAggg96YCkZ74ooooAKKKKACiiigAooooAKKKKACgUnPfFKKACiiigAqK7t4by1mtrmNZbeZGjkjYZDKRgg+xBqWigD55ufDvjb4cWcllp2jr4q8NQFhZ/ZZdl3AhOQkikHeBnGVz07dKzrLwX8QPijDLD4iVvB3h04PkKu+5uPYjIIH1x9DX0vRWrrzceW5PJG97HjmnfCLxBpsEFrZfEG7WwgXZHA+lwttXHABz/Sus8IfDjSvD9+NTuZ7vWNaG7bf6g+94geqxqMKg+gz7129FS6kmrNjUUtT5wM6a54m1vS1tZpDLr09zeOB8kUcLKqKT/eYqvHpXdrbXN3MUhQvJyQEHNdVq/gHw/qeoz6g9rJbX84xNPaTvA0mO7bSAx9yM1f8L+HLXw5bTQWdxe3CyvvLXc5lYH0BPb2rqhi1CFktTJ0ru9zym91HxCk+yy8D63ew/8APbMcQOPRWbP8qhl8Q6lZ7v7T8EeKIUUZLxWqzr/44xr3eio+tzH7GJ4BD4+8MtJ5d3ftp0u3PlahBJbsP++gBW7p2qabqKK+m6lZ3QIz+5mVzj8DXrd1aW93GY7uCKeMjBWVAwP4GuQ1j4V+CNXLNd+GtPWQ/wDLS3TyH/NMGrjjH1RLo9jnpI3Ax0Oc80kbNuQZxjuO9TXHwcs4dx0HxN4j0vgBYhdCeJAOwWQE4/Gsq88GfETS332Gq6Hr8Kg/u7uBrSX8GTK/nWyxcHuS6UkXbjZcqYruGKVGOAsqBh+RrmtU+H/hHUnaS60CzWUn79vmFs+uUIqS71vxRpbFNb+H+sBBkGbTHS8XjuAuCBVSy+Ivhm4cQXF+2nzg48rUIXtyP++hj9a0VSnMjllEZb+CbvTXH/CO+NPE2mCMYSI3XnxKPTY/FaEWsfFTRsmDV9A8QQgfdvLY28mfqnH51pWl1ZX0fmWV9aTrnJMMyt1+hq4YGwB5Z2g560PD0pdPuGqk11KNv8WfFlmZF1v4fXEuznzNNvUlBHqFYA1oxfHPw/Gp/tTR/EumsOouNNYj81JqJgYxuySp644NEsjqN3I7cn8qylgoPZspV31NSL42eBmQtLqdzAB186wnXH/jlTD40fD/AIz4jhXIz89vMv8ANKwy0gQByWx2PNNZvM4ljRiRwCoOan6kv5hqv5GpqXxJ+FmuR/Z9V1rRLyMDIW7j3KP++l4NULOX4cRDzPDfje30clflW01lRGP+2UjFfwxVSWxtXjxJYWrhuNrwqQf0qinhrRcM39i6Uz98WkfP6VDwX978P+CNV/ItaxfrcwLb33iTwB4vshjCanLFBOfZWQsmffaK5s61pGhzKsNx4k8IyEZDadfx6nYKT/sbm4+iitz/AIRPw5L9/wAP6Tk8c2iD+lOj8EeFlRFHh3TNx6/6Ov8AhUvB/wB78P8AgjVddiTQvibqFyduj+JfB/idR8qQyytpl3I2f7r5X8gK7VfHs1sY11nwp4is2brJBbC8iHvviLcfhXBy/DTwXcxtHL4Z09Qy43IChz9QeKjsvh1p+k/8i7rGvaC2P+XO+cp17o+QfpUPCyWz/r8Svap9Dpb/AOPPgCxLrdapdxSISCj2E6tn05Uc1Usfjvo+qLnRPDnifUM/dMVmoBHrkvwPrVGTTPH9rCsUHivStbhBJEWtaapP/fUeP5VzPiz+0dHtbT/hIvhx4O1J9Ruks1OmTtbPJI+do5XI6cnNZulJbr8iudPY7Bfi34kulZ9N+GGvzRKT8006QkgHBwCDmtEeP/G00WbX4Y33mMuV87U4EX8TXmo0zTNNcfaPg1r0KjK7rHWHnGO+AHFXYLnwiUCT/DX4gJkYZAJ3A/8AI1Llt0f9fIL36o6288cfEWBXa58M+GNKiAz51/ri7V+uADXL6p8Q/ilaeL9J0CMeDri41RI5IJbYTSRKrMwzuzyAFY8dhWXq6+F3E0Oj/BPxHqTzpsaS9jki+hDFnI+owa0/gpYDUvHupaqtg1lZaPZx2FpbuMi3cja6Lyem1+Sc/NQorqvzHex3mj+IvGOi+NtI0Txp/Yt5Z6wkq2t3pqvG0U0abyrqxOQRnBFenV55ry/bvi14NtYsM2nW15fz8/dVlESZHuWP5GvQ6hjExz7UtITgUo60gCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVr6ws9Qi8q/tLe5i/uTRhx+RFWaKAOC1H4QeAdQmMs3hmxjkPVrbdB+iECsy6+CHhV33afca7pftZanIo/Ji1eoUU1JrZisjx6T4JGMMbHx14rhcj5TJcJIB9QV5qrL8I/FwUCH4kXDgcgTaZG2fqd1e10VaqzXUXKjxCT4afEWLetv450yZT087SgpH5E1BF8P/ikku0+I/DBTH+sNnIWz6YxivdqKft6ncOSPY8P/AOFffE6QgSeK/D8QzyY9PZj9eaU/C/4gyFvM+INpFn/nlpKf1Ne30Ue2n3FyR7Hir/Czx06AD4jhWyT8ukx//FdKaPhV483bj8T5sgcAaVHj/wBCr2yil7afcfIjw5/hh8SYVZrX4kwyyZyFm0tAv5gn+VQS+DfjLb/ND4l8M3oH8EtsybvyT+te8UUvaS7hyo8HhsvjXCzK+meEJlzwRLIoP61n61oPxeuvFukazcaJ4fu7fTFdoLCC9KR+Yy4LsWwSwHTsK+iKKHUk+o+VHiR8SfE+zy9z8M4pY9vItdWiZvyqi/xqttGkWLxl4S8SeH9x5mmt98X/AH1wT+Ar3umSxpLGUlRXQ9VYZB/Cj2jFyo8ol+LHhOTwnqGraX4hsZpY4WMcLSbJWkxhV2Ng9SO1V/gw2leHvhimrX2rWiWt/cSXktxM4jUHO3GSfVf1rp9Z+EfgLWGma88L6cJJfvPBH5LZ9QUxiqWh/BL4f6NOstv4finZTlFu5XnRT6hHJX9Kbl2BRL3w5WXVdU1/xTPCyQ6jMkOns4+ZrOJcKwHUBmLtj3BruqRVCqAoAA4AHalrMoax9QeTThSEZpRSAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The brachioradialis is relaxed in supination but may become a deforming force in pronation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15072=[""].join("\n");
var outline_f14_46_15072=null;
var title_f14_46_15073="Pseudosac";
var content_f14_46_15073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrial pseudosac",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of the uterus demonstrates a centrally located fluid collection without echogenic ring (arrow), representing a pseudosac. The patient had surgically proven ectopic pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15073=[""].join("\n");
var outline_f14_46_15073=null;
var title_f14_46_15074="Cervical vertebrae anatomy PI";
var content_f14_46_15074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 543px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15074=[""].join("\n");
var outline_f14_46_15074=null;
var title_f14_46_15075="Ultrasound tibialis anterior with foot inversion";
var content_f14_46_15075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the tibialis anterior with foot inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are axial images of the tibialis anterior with the foot in neutral position (left, A) and with the foot inverted (right, B). Note that the interosseus membrane (arrows) bulges out with foot inversion due to thickening of the tibialis posterior muscle that lies just deep to it. Needle electromyography or therapeutic botulinum toxin injections can be guided by ultrasound through the anterior tibialis to locate this muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15075=[""].join("\n");
var outline_f14_46_15075=null;
var title_f14_46_15076="Alpha-1 proteinase inhibitor: Drug information";
var content_f14_46_15076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alpha-1 proteinase inhibitor: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/57/29587?source=see_link\">",
"    see \"Alpha-1 proteinase inhibitor: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aralast NP;",
"     </li>",
"     <li>",
"      Glassia&trade;;",
"     </li>",
"     <li>",
"      Prolastin&reg;-C;",
"     </li>",
"     <li>",
"      Zemaira&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prolastin&reg;-C",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitrypsin Deficiency Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha",
"     <sub>",
"      1",
"     </sub>",
"     -antitrypsin deficiency: I.V.: 60 mg/kg once weekly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [human, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aralast NP: ~ 500 mg, ~ 1000 mg [contains polysorbate 80, sodium &le;230 mEq/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prolastin&reg;-C: ~ 1000 mg [contains sodium 100-210 mEq/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zemaira&reg;: ~ 1000 mg [contains sodium 81 mEq/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [human, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glassia&trade;: ~ 1000 mg (50 mL) [contains polysorbate 80, sodium 6.5-8.5 mEq/vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. infusion only. Administer within 3 hours of preparation; products do not contain a preservative. Do not mix with other agents or solutions. If adverse reactions occur during administration, rate may be decreased or temporarily interrupted. Some products require an in-line filter for administration; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aralast NP: Infuse at a rate of &le;0.08 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glassia&trade;: Infuse at rate of &le;0.04 mL/kg/minute. Infusion may be administered directly from the vial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prolastin&reg;-C, Zemaira&reg;: Infuse at ~0.08 mL/kg/minute (rate may be increased or decreased based on patient comfort).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy in congenital alpha",
"     <sub>",
"      1",
"     </sub>",
"     -proteinase inhibitor (alpha",
"     <sub>",
"      1",
"     </sub>",
"     -antitrypsin, A",
"     <sub>",
"      1",
"     </sub>",
"     -PI) deficiency with clinical emphysema",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Actual incidence may vary by product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, peripheral edema, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, lightheadedness, malaise, migraine, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flushes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, bloating, cholangitis, diarrhea, dyspepsia, nausea, sore throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (including hemorrhage and pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, musculoskeletal discomfort,  paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Vision changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, bronchitis, bronchospasm, COPD exacerbation, cough, dyspnea, pharyngitis, respiratory tract infection (lower/upper), rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic reactions (severe anaphylactic reactions may occur in patients with anti-IgA antibody), hypersensitivity reaction, hyper-/hypotension, interstitial lung disease, pulmonary infiltrate, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation or other A",
"     <sub>",
"      1",
"     </sub>",
"     -PI products; IgA deficient patients with known anti-IgA antibody",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; stop infusion promptly for acute hypersensitivity; immediate treatment (including epinephrine 1:1000) should be available. May contain trace amounts of IgA; severe anaphylaxis may occur in patients with anti-IgA antibody; use in patients with selective IgA deficiency with known anti-IgA antibody is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: Plasma volume may increase following infusion; use with caution in patients at risk for fluid overload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: May consider hepatitis B immunization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F131968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Glassia Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg/50 mL (1): $0.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Aralast NP Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (1): $0.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $0.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (1): $0.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $0.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Prolastin-C Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $0.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zemaira Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $0.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha",
"     <sub>",
"      1",
"     </sub>",
"     -PI serum levels; lung function; vital signs during infusion",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F131969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Prolastin (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha",
"     <sub>",
"      1",
"     </sub>",
"     -antitrypsin (AAT) is the principle protease inhibitor in  serum. Its major physiologic role is to render proteolytic enzymes (secreted during inflammation) inactive. A decrease in AAT, as seen in congenital AAT deficiency, leads to increased elastic damage in the lung, causing emphysema.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Metabolic: ~5-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour; threshold levels achieved after 3 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society/European Respiratory Society Statement: &ldquo;Standards for the Diagnosis and Management of Individuals With Alpha-1 Antitrypsin Deficiency,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 168(7):818-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15076/abstract-text/14522813/pubmed\" id=\"14522813\" target=\"_blank\">",
"        14522813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Louie SG, Sclar DA, and Gill MA, &ldquo;Aralast: A New Alpha1-Protease Inhibitor for Treatment of Alpha-Antitrypsin Deficiency,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(11):1861-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15076/abstract-text/16219903/pubmed\" id=\"16219903\" target=\"_blank\">",
"        16219903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stoller JK and Aboussouan LS, &ldquo;Alpha1-Antitrypsin Deficiency,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005,  365(9478):2225-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15076/abstract-text/15978931/pubmed\" id=\"15978931\" target=\"_blank\">",
"        15978931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8495 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15076=[""].join("\n");
var outline_f14_46_15076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131989\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131978\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131979\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671398\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671399\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131961\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131949\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131963\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131962\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131987\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131966\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131953\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298714\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217702\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131958\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131967\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131982\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131968\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322971\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131959\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131969\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131952\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131965\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/57/29587?source=related_link\">",
"      Alpha-1 proteinase inhibitor: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_46_15077="Retained tube";
var content_f14_46_15077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retained tympanostomy tube with squamous debris creeping into the middle ear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retained tympanostomy tube with squamous debris creeping into the middle ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15077=[""].join("\n");
var outline_f14_46_15077=null;
var title_f14_46_15078="Penbutolol: Drug information";
var content_f14_46_15078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penbutolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/38/42596?source=see_link\">",
"    see \"Penbutolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levatol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levatol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker With Intrinsic Sympathomimetic Activity",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 20 mg once daily, full effect of a 20 or 40 mg dose is seen by the end of a 2-week period, doses of 40-80 mg have been tolerated but have shown little additional antihypertensive effects; usual dose range (JNC 7): 10-40 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levatol&reg;: 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate arterial hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Levatol&reg; may be confused with Lipitor&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Levatol [U.S.] may be confused with Lovacol brand name for lovastatin [Chile and Finland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, CHF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, mental depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): AV block, bradycardia, bronchospasm, hyperglycemia, hypotension, impotence, ischemic colitis, mesenteric arterial thrombosis, Raynaud's phenomena, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penbutolol or any component of the formulation; uncompensated congestive heart failure; cardiogenic shock; bradycardia or heart block (except in patients with a functioning artificial pacemaker); sinus node dysfunction; asthma; bronchospastic disease; COPD; pulmonary edema; pregnancy (2nd and 3rd trimester)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition (beta-blockers with intrinsic sympathomimetic activity have not been demonstrated to be of value in HF).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10537424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Adverse events were observed in animal reproduction studies; therefore, the manufacturer classifies penbutolol as pregnancy category C. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. Protein binding of penbutolol is decreased during the 2nd and 3rd trimesters of pregnancy. Limited information is available related to the use of penbutolol for the treatment of hypertension in pregnancy; other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F207336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if penbutolol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering penbutolol to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F207335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Levatol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $406.80",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betapressin (AT, CH, CZ, DE, FR, IT);",
"     </li>",
"     <li>",
"      Betapressine (FR);",
"     </li>",
"     <li>",
"      Hostabloc (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors and has mild intrinsic sympathomimetic activity; has negative inotropic and chronotropic effects and can significantly slow AV nodal conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 1.3-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic (oxidation and conjugation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Penbutolol: 5 hours; Conjugated metabolite: ~20 hours with normal renal function, 100 hours with end-stage renal disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15078/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15078/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15078/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15078/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15078/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15078/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10199 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15078=[""].join("\n");
var outline_f14_46_15078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207345\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207346\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207366\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207349\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207350\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207329\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207315\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207330\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207370\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207364\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207333\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207319\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299835\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207324\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207325\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10537424\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207351\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207336\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207335\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207337\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207332\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/38/42596?source=related_link\">",
"      Penbutolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_46_15079="Vecuronium: Drug information";
var content_f14_46_15079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vecuronium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/46/37603?source=see_link\">",
"    see \"Vecuronium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/49/43797?source=see_link\">",
"    see \"Vecuronium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norcuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Nondepolarizing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose to effect; doses will vary due to interpatient variability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical relaxation:",
"     </b>",
"     I.V. (do not administer I.M.):",
"     <b>",
"      Note:",
"     </b>",
"     For obese (&ge;130% of IBW) adult patients, may use ideal body weight (IBW) (Erstad, 2004; Schwartz, 1992; Weinstein, 1988); onset time may be slightly delayed using IBW.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tracheal intubation: I.V.: Initial: 0.08-0.1 mg/kg.",
"     <b>",
"      Note:",
"     </b>",
"     If intubation is performed using succinylcholine (not preferred agent in pediatric patients), the initial dose of vecuronium may be reduced to 0.04-0.06 mg/kg with inhalation anesthesia and 0.05-0.06 mg/kg with balanced anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Pretreatment/priming:",
"     </i>",
"     Adults: 10% of intubating dose given 3-5 minutes before intubating dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance for continued surgical relaxation (only after return of neuromuscular function): Intermittent dosing: 0.01-0.015 mg/kg",
"     <b>",
"      or",
"     </b>",
"     continuous infusion of 0.8-1.2 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use lower end of the dosing range when anesthesia is maintained with an inhaled anesthetic agent, with the redosing interval guided by monitoring with a peripheral nerve stimulator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ICU paralysis (eg, facilitate mechanical ventilation) in selected adequately sedated patients (Darrah, 1989; Murray, 2002; Rudis, 1997):",
"     </b>",
"     I.V.: Initial bolus dose: 0.08-0.1 mg/kg, then a continuous I.V. infusion of 0.8-1.7 mcg/kg/minute; monitor depth of blockade every 1-2 hours initially until stable dose, then every 8-12 hours. Usual maintenance infusion dose range: 0.8-1.2 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment",
"     </i>",
"     (Rudis, 1996; Rudis, 1997): Adjust rate of administration in increments of 0.3 mcg/kg/minute or by 50% reductions of previous dose according to peripheral nerve stimulation response or desired clinical response. Discontinue infusion if neuromuscular function does not return.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When possible, minimize depth and duration of paralysis. Stopping the infusion daily for some time until forced to restart based on patient condition is recommended to reduce post-paralytic complications (eg, acute quadriplegic myopathy syndrome [AQMS]) (Murray, 2002; Segredo, 1992).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intermittent bolus dosing",
"     </i>",
"     (Hunter, 1985): 0.1-0.2 mg/kg/dose; may be repeated when neuromuscular function returns",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Control of refractory shivering in adequately sedated patients during therapeutic hypothermia after cardiac arrest (unlabeled use; Bernard, 2002; Nolan, 2003; Polderman, 2009):",
"     </b>",
"     I.V.: 8-12 mg; redose as needed to control shivering.",
"     <b>",
"      Note:",
"     </b>",
"     Duration of action prolonged in hypothermic patients. May mask seizure activity.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F233689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/49/43797?source=see_link\">",
"      see \"Vecuronium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose to effect; doses will vary due to interpatient variability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Surgical relaxation:",
"     </b>",
"     Tracheal intubation: I.V. (do not administer I.M.): Children &ge;1 year: Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Children 1-10 years may require slightly higher initial doses and more frequent supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ICU paralysis (eg, facilitate mechanical ventilation) in selected adequately sedated patients (unlabeled; Martin, 1999):",
"     </b>",
"     I.V.: Initial bolus dose: 0.1-0.15 mg/kg, then a continuous I.V. infusion of 1-2.5 mcg/kg/minute; monitor depth of blockade using peripheral nerve stimulator every 2-3 hours initially until stable dose, then every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intermittent bolus dosing",
"     </i>",
"     (Eldadah, 1989): 0.1 mg/kg every 1 hour as needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific guidelines available; refer to adult dosing. Dose selection should be cautious, at low end of dosage range, and titration should be slower to evaluate response.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7689123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, patients with renal impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium; however, in patients who are anephric, the clinical duration is prolonged.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose reductions are necessary in patients with liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as bromide: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concentration of 1 mg/mL may be administered by rapid I.V. injection; may also be used for I.V. infusion in fluid-restricted patients.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10 mg in 100 mL (concentration: 0.1 mg/mL), 20 mg in 100 mL (concentration: 0.2 mg/mL),",
"     <b>",
"      or",
"     </b>",
"     50 mg in 50 mL (concentration: 1 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.1 mg/mL, 0.2 mg/mL, 1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F233713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS, SWI, BWFI;",
"     <b>",
"      incompatible",
"     </b>",
"     with alkaline solutions/medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alprostadil, aminophylline, amiodarone, cefazolin, cefuroxime, cimetidine, diltiazem, dobutamine, dopamine, epinephrine, esmolol, fenoldopam, fentanyl, fluconazole, gentamicin, heparin, hetastarch in lactate electrolyte solution (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, isoproterenol, labetalol, linezolid, lorazepam, midazolam, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, norepinephrine, palonosetron, ranitidine, trimethoprim/sulfamethoxazole, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, diazepam, etomidate, furosemide, micafungin, pantoprazole, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible",
"     </b>",
"     with pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To facilitate endotracheal intubation and to relax skeletal muscles during surgery; to facilitate mechanical ventilation in ICU patients; does not relieve pain or produce sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vecuronium may be confused with valproate sodium, vancomycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norcuron&reg; may be confused with Narcan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Acute quadriplegic myopathy syndrome (prolonged use), Bradycardia, circulatory collapse, edema, flushing; hypersensitivity reaction (hypotension, tachycardia, erythema, rash, urticaria); itching, myositis ossificans (prolonged use), rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vecuronium or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged paralysis: Some patients may experience delayed recovery of neuromuscular function after administration (especially after prolonged use). Other factors associated with delayed recovery should be considered (eg, corticosteroid use, disease-related conditions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn injury: Resistance may occur in burn patients (&gt;30% of body) for period of 5-70 days postinjury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may",
"     <i>",
"      antagonize",
"     </i>",
"     neuromuscular blockade: Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, and muscle trauma may result in antagonism of neuromuscular blockade; dosage increase may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may",
"     <i>",
"      potentiate",
"     </i>",
"     neuromuscular blockade: Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, cachexia, neuromuscular diseases, acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade; dosage reduction may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: In general, patients with renal impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium; however, in patients who are anephric, the clinical duration may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with underlying respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroids: In addition to prolonging recovery from neuromuscular blockade, concomitant use with corticosteroids has been associated with development of acute quadriplegic myopathy syndrome (AQMS). Current guidelines recommend neuromuscular blockers be discontinued as soon as possible in patients receiving corticosteroids or interrupted daily until necessary to restart them based on clinical condition (Murray, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Numerous drugs either",
"     <i>",
"      antagonize",
"     </i>",
"     (eg, acetylcholinesterase inhibitors) or",
"     <i>",
"      potentiate",
"     </i>",
"     (eg, calcium channel blockers, certain antimicrobials, inhalation anesthetics) the effects of neuromuscular blockade; use with caution in patients receiving these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, effects and duration are more variable; dosage reduction may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immobilized patients: Resistance may occur in patients who are immobilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children 1-10 years of age may require slightly higher initial doses and slightly more frequent supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. Vecuronium does not relieve pain or produce sedation; use should include appropriate anesthesia, pain control, and sedation.  In patients requiring long-term administration, use of a peripheral nerve stimulator to monitor drug effects is strongly recommended. Additional doses of vecuronium or any other neuromuscular-blocking agent should be avoided unless nerve stimulation response suggests inadequate neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered by adequately trained individuals familiar with its use.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dantrolene: May enhance the neuromuscular-blocking effect of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Vecuronium. Fosphenytoin may enhance the therapeutic effect of Vecuronium. Fosphenytoin may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the therapeutic effect of Vecuronium. Phenytoin may diminish the therapeutic effect of Vecuronium. Phenytoin may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Use in cesarean section has been reported. Umbilical venous concentrations were 11% of maternal. Use only if the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Vecuronium Bromide Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $6.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $14.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; peripheral nerve stimulation (eg, train-of-four [TOF] count)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ecron (ID);",
"     </li>",
"     <li>",
"      Nodescr&oacute;n (MX);",
"     </li>",
"     <li>",
"      Norcuron (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IN, IQ, IR, IT, JO, KP, KW, LB, LU, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SE, SK, SY, TR, VE, YE);",
"     </li>",
"     <li>",
"      Vecural (PY, UY);",
"     </li>",
"     <li>",
"      Vecuron (PH, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Good intubation conditions: Within 2.5-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum neuromuscular blockade: Within 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Under balanced anesthesia (time to recovery to 25% of control): 25-40 minutes; recovery 95% complete ~45-65 minutes after injection of intubating dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.3-0.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Active metabolite: 3-desacetyl vecuronium (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the activity of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Healthy surgical patients and renal failure patients undergoing transplant surgery: 65-75 minutes; Late pregnancy: 35-40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces (40% to 75%); urine (30% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bernard SA, Gray TW, Buist MD, et al, &ldquo;Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(8):557-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/11856794/pubmed\" id=\"11856794\" target=\"_blank\">",
"        11856794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Darrah WC, Johnston JR, Mirakhur RK, &ldquo;Vecuronium Infusions for Prolonged Muscle Relaxation in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1989, 17(12):1297-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/2574099/pubmed\" id=\"2574099\" target=\"_blank\">",
"        2574099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eldadah MK and Newth CJ, &ldquo;Vecuronium by Continuous Infusion for Neuromuscular Blockade in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1989, 17(10):989-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/2571460/pubmed\" id=\"2571460\" target=\"_blank\">",
"        2571460",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL, &ldquo;Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2004, 30(1):18-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/14625670/pubmed\" id=\"14625670\" target=\"_blank\">",
"        14625670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunter JM, Parker CJR, Bess CF, et al, &ldquo;The Use of Different Doses of Vecuronium in Patients With Liver Dysfunction,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1985, 57(8):758-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/2861836/pubmed\" id=\"2861836\" target=\"_blank\">",
"        2861836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin LD, Bratton SL, and O&rsquo;Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(7):1358-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/10446832/pubmed\" id=\"10446832\" target=\"_blank\">",
"        10446832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):142-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/11902255/pubmed\" id=\"11902255\" target=\"_blank\">",
"        11902255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nolan JP, Morley PT, Vanden Hoek TL, et al, &ldquo;Therapeutic Hypothermia After Cardiac Arrest: An Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(1):118-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/12847056/pubmed\" id=\"12847056\" target=\"_blank\">",
"        12847056",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS and Williams RL, &ldquo;Improving the Safety of Neuromuscular Blocking Agents: A Statement from the USP Safe Medication Use Expert Committee,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(2):139-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/16390927/pubmed\" id=\"16390927\" target=\"_blank\">",
"        16390927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polderman KH and Herold I, &ldquo;Therapeutic Hypothermia and Controlled Normothermia in the Intensive Care Unit: Practical Considerations, Side Effects, and Cooling Methods,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(3):1101-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/19237924/pubmed\" id=\"19237924\" target=\"_blank\">",
"        19237924",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudis MI, Guslits BG, and Zarowitz BJ, &ldquo;Technical and Interpretive Problems of Peripheral Nerve Stimulation in Monitoring Neuromuscular Blockade in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(2):165-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/8835051/pubmed\" id=\"8835051\" target=\"_blank\">",
"        8835051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudis MI, Sikora CA, Angus E, et al, &ldquo;A Prospective, Randomized, Controlled Evaluation of Peripheral Nerve Stimulation Versus Standard Clinical Dosing of Neuromuscular Blocking Agents in Critically Ill Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1997, 25(4), 575-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/9142020/pubmed\" id=\"9142020\" target=\"_blank\">",
"        9142020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz AE, Matteo RS, Ornstein E, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1992, 74(4):515-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/1348166/pubmed\" id=\"1348166\" target=\"_blank\">",
"        1348166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Segredo V, Caldwell JE, Matthay MA, et al, &ldquo;Persistent Paralysis in Critically Ill Patients After Long-term Administration of Vecuronium,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(8):524-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/1353252/pubmed\" id=\"1353252\" target=\"_blank\">",
"        1353252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinstein JA, Matteo RS, Ornstein E, et al, &ldquo;Pharmacodynamics of Vecuronium and Atracurium in the Obese Surgical Patient,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1988, 67(12):1149-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15079/abstract-text/2904232/pubmed\" id=\"2904232\" target=\"_blank\">",
"        2904232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10041 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15079=[""].join("\n");
var outline_f14_46_15079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708859\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233672\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233707\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233674\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233689\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233675\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7689123\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233676\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233649\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233635\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233652\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473224\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473225\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233713\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233650\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233715\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233706\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233655\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233639\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300211\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233643\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233645\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233658\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233679\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324085\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233647\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233659\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233638\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233654\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/46/37603?source=related_link\">",
"      Vecuronium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/49/43797?source=related_link\">",
"      Vecuronium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_46_15080="Quinine: Drug information";
var content_f14_46_15080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/0/13317?source=see_link\">",
"    see \"Quinine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=see_link\">",
"    see \"Quinine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9776905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3343866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Qualaquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quinine&reg;;",
"     </li>",
"     <li>",
"      Novo-Quinine;",
"     </li>",
"     <li>",
"      Quinine-Odan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Actual duration of quinine treatment for malaria may be dependent upon the geographic region or pathogen. Dosage expressed in terms of the salt; 1 capsule Qualaquin&reg; = 324 mg of quinine sulfate = 269 mg of base.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Treatment of uncomplicated chloroquine-resistant",
"     </b>",
"     <b>",
"      <i>",
"       P. falciparum",
"      </i>",
"     </b>",
"     <b>",
"      malaria (CDC guidelines):",
"     </b>",
"     Oral: 648 mg every 8 hours for 3-7 days. Tetracycline, doxycycline, or clindamycin should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of uncomplicated chloroquine-resistant",
"     </b>",
"     <b>",
"      <i>",
"       P. vivax",
"      </i>",
"     </b>",
"     <b>",
"      malaria (unlabeled use; CDC guidelines):",
"     </b>",
"     Oral: 648 mg every 8 hours for 3-7 days. Tetracycline or doxycycline plus primaquine should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Babesiosis (unlabeled use):",
"     </b>",
"     Oral: 650 mg every 6-8 hours for 7-10 days with clindamycin (Wormser, 2006; Vannier, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Relapsing infection may require at least 6 weeks of therapy (Vannier, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=see_link\">",
"      see \"Quinine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Actual duration of quinine treatment for malaria may be dependent upon the geographic region or pathogen. Dosage expressed in terms of the salt; 1 capsule Qualaquin&reg; = 324 mg of quinine sulfate = 269 mg of base.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Treatment of uncomplicated chloroquine-resistant",
"      <b>",
"       <i>",
"        P. falciparum",
"       </i>",
"      </b>",
"      malaria (CDC guidelines):",
"     </b>",
"     Oral: 30 mg/kg/day in divided doses every 8 hours for 3-7 days. Tetracycline, doxycycline, or clindamycin (consider risk versus benefit of using tetracycline or doxycycline in children &lt;8 years) should also be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of uncomplicated chloroquine-resistant",
"     </b>",
"     <b>",
"      <i>",
"       P. vivax",
"      </i>",
"     </b>",
"     <b>",
"      malaria (unlabeled use; CDC guidelines):",
"     </b>",
"     Oral: 30 mg/kg/day in divided doses every 8 hours for 3-7 days. Tetracycline or doxycycline (consider risk versus benefit of using tetracycline or doxycycline in children &lt;8 years) plus primaquine should also be given.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe chronic renal failure not on dialysis: Initial dose: 648 mg followed by 324 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Administer dose after dialysis.",
"     <b>",
"      Note:",
"     </b>",
"     Clearance of ~6.5% achieved with 1 hour of hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Not removed by hemo- or peritoneal dialysis; dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or hemodialysis: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3343960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosing adjustment required; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Data not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sulfate: 324 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Qualaquin&reg;: 324 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9662364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM192698.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM192698.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use of aluminum- or magnesium-containing antacids because of drug absorption problems. Swallow dose whole to avoid bitter taste. May be administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In conjunction with other antimalarial agents, treatment of uncomplicated  chloroquine-resistant",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F216588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      Babesia microti",
"     </i>",
"     infection in conjunction with clindamycin; treatment of uncomplicated chloroquine-resistant",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria (in conjunction with other antimalarial agents)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       QuiNINE may be confused with quiNIDine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, chest pain, hypotension, irregular rhythm, nodal escape beats, orthostatic hypotension, palpitation, QT prolongation, syncope, tachycardia, torsade de pointes, unifocal premature ventricular contractions, U waves, vasodilation, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aphasia, ataxia, chills, coma, confusion, disorientation, dizziness, dystonic reaction, fever, flushing, headache, mental status altered, restlessness, seizure, suicide, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acral necrosis, allergic contact dermatitis, bullous dermatitis, bruising, cutaneous rash (urticaria, papular, scarlatinal), cutaneous vasculitis, exfoliative dermatitis, erythema multiforme, petechiae, photosensitivity, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, esophagitis, gastric irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, coagulopathy, disseminated intravascular coagulation, hemolytic anemia, hemolytic uremic syndrome, hemorrhage, hypoprothrombinemia, idiopathic thrombocytopenic purpura, leukopenia, neutropenia, pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Granulomatous hepatitis, hepatitis, jaundice, liver function test abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, blurred vision (with or without scotomata), color vision disturbance, diminished visual fields, diplopia, night blindness, optic neuritis, photophobia, pupillary dilation, vision loss (sudden)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, hearing impaired, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, hemoglobinuria, renal failure, renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Black water fever, diaphoresis, hypersensitivity reaction, lupus anticoagulant, lupus-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinine or any component of the formulation; hypersensitivity to mefloquine or quinidine (cross sensitivity reported); history of potential hypersensitivity reactions (including black water fever, thrombotic thrombocytopenia purpura [TTP], hemolytic uremic syndrome [HUS], or thrombocytopenia) associated with prior quinine use; prolonged QT interval; myasthenia gravis; optic neuritis; G6PD deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions (eg, Stevens-Johnson syndrome, anaphylactic shock) have occurred;  discontinue following any signs of sensitivity. Other events (including acute interstitial nephritis, neutropenia, and granulomatous hepatitis) may also be attributed to hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: Use may cause significant hypoglycemia due to quinine-induced insulin release.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Immune-mediated thrombocytopenia, including life-threatening cases and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), has occurred with use. Chronic renal failure associated with TTP has also been reported. Thrombocytopenia generally resolves within a week upon discontinuation. Re-exposure may result in increased severity of thrombocytopenia and faster onset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Use with caution in patients with atrial fibrillation or flutter. Use with caution in patients with clinical conditions which may prolong the QT interval or cause cardiac arrhythmias. Quinine may cause QT interval prolongation, with maximum increase corresponding to maximum plasma concentration. Use contraindicated in patients with QT prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolonging agents: Use caution with medications which may further prolong the QT interval or cause cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Quinine should not be used for the prevention of malaria or in the treatment of complicated or severe",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria (oral antimalarial agents are not appropriate for initial therapy of severe malaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nocturnal leg cramps:",
"     <b>",
"      [U.S. Boxed Warning]: Quinine is not recommended for the prevention/treatment of nocturnal leg cramps due to the potential for severe and/or life-threatening side effects (eg, cardiac arrhythmias, thrombocytopenia, and HUS/TTP, severe hypersensitivity reactions).",
"     </b>",
"     These risks, as well as the absence of clinical effectiveness, do not justify its use in the unapproved/unlabeled prevention and/or treatment of leg cramps.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate), CYP2D6 (moderate), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of QuiNINE.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Carbonate; Sodium Bicarbonate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Herbs (Hypotensive Properties) may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: QuiNINE may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: QuiNINE may enhance the adverse/toxic effect of Halofantrine. QuiNINE may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the adverse/toxic effect of other Herbs (Hypotensive Properties). Excessive blood pressure lowering may manifest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: QuiNINE may increase the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pitavastatin; Pravastatin; Red Yeast Rice; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of QuiNINE.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: QuiNINE may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of QuiNINE.  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinine when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: QuiNINE may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: QuiNINE may increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: QuiNINE may increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): QuiNINE may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F216568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease quinine levels. Black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, and shepherd's purse may cause excessive decreases in blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3343867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in some animal studies. Quinine crosses the human placenta. Cord plasma to maternal plasma quinine ratios have been reported as 0.18-0.46 and should not be considered therapeutic to the infant. Teratogenic effects, optic nerve hypoplasia, and deafness have been reported in the infant following maternal use of very high doses; however, therapeutic doses used for malaria are generally considered safe. Quinine may also cause significant hypoglycemia when used during pregnancy. Malaria infection in pregnant women may be more severe than in nonpregnant women. Because",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Quinine may be used for the treatment of malaria in pregnant women; consult current CDC guidelines. Pregnant women should be advised not to travel to areas of",
"     <i>",
"      P. falciparum",
"     </i>",
"     resistance to chloroquine.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rate \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3343869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on limited data, it is estimated that nursing infants would receive &lt;0.4% of the maternal dose from breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F216559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food to decrease incidence of gastric upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4380080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Qualaquin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     324 mg (30): $235.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (QuiNINE Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     324 mg (30): $212.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F554010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC with platelet count, liver function tests, blood glucose, ophthalmologic examination",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aethylcarbonis Chinin (ID);",
"     </li>",
"     <li>",
"      Circonyl (AR);",
"     </li>",
"     <li>",
"      Genin (TH);",
"     </li>",
"     <li>",
"      Kinin (DK, SE);",
"     </li>",
"     <li>",
"      Q200 (HK, NZ);",
"     </li>",
"     <li>",
"      Q300 (HK, NZ);",
"     </li>",
"     <li>",
"      Quinate (AU);",
"     </li>",
"     <li>",
"      Quinbisu (AU);",
"     </li>",
"     <li>",
"      Quinimax (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Quininga (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses oxygen uptake and carbohydrate metabolism; intercalates into DNA, disrupting the parasite's replication and transcription; cardiovascular effects similar to quinidine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily, mainly from upper small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Children: ~0.9 L/kg (subjects with malaria); Adults: 2.5-7.1 L/kg (varies with severity of infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intraerythrocytic levels are ~30% to 50% of the plasma concentration; distributes poorly to the CSF (~2% to 7% of plasma concentration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 69% to 92% in healthy subjects; 78% to 95% with malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP450 enzymes, primarily CYP3A4; forms metabolites; major metabolite, 3-hydroxyquinine, is less active than parent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 76% to 88% in healthy subjects; increased with malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: ~3 hours in healthy subjects; ~12 hours with malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Healthy adults: 10-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Healthy elderly subjects: 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2 hours in healthy subjects; 4 hours with malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4 hours in healthy subjects; 1-11 hours with malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Berns JS, Brier ME, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults",
"      </i>",
"      , 4th ed. Philadelphia, PA: American College of Physicians; 1999, p 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bateman DN, Blain PG, Woodhouse KW, et al, &ldquo;Pharmacokinetics and Clinical Toxicity of Quinine Overdosage: Lack of Efficacy of Techniques Intended to Enhance Elimination,&rdquo;",
"      <i>",
"       Q J Med",
"      </i>",
"      , 1985, 54(214):125-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/3983356/pubmed\" id=\"3983356\" target=\"_blank\">",
"        3983356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boland ME, Roper SM, and Henry JA, &ldquo;Complications of Quinine Poisoning,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1985, 1(8425):384-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Treatment Guidelines From the Medical Letter",
"      </i>",
"      , 2004, 50(Suppl):e1-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dyson EH, Proudfoot AT, and Bateman DN, &ldquo;Quinine Amblyopia: Is Current Management Appropriate?&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1985-6, 23(7-8):571-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaeger A, Sauder P, Kopferschmitt J, et al, &ldquo;Clinical Features and Management of Poisoning Due to Antimalarial Drugs,&rdquo;",
"      <i>",
"       Med Toxicol Adverse Drug Exp",
"      </i>",
"      , 1987, 2(4):242-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/3306266/pubmed\" id=\"3306266\" target=\"_blank\">",
"        3306266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lockey D and Bateman DN, &ldquo;Effect of Oral Activated Charcoal on Quinine Elimination,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1989, 27(1):92-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/2706191/pubmed\" id=\"2706191\" target=\"_blank\">",
"        2706191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newman RD, Parise ME, Slutsker L, et al, &ldquo;Safety, Efficacy and Determinants of Effectiveness of Antimalarial Drugs During Pregnancy: Implications for Prevention Programmes in",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      -Endemic Sub-Saharan Africa,&rdquo;",
"      <i>",
"       Trop Med Int Health",
"      </i>",
"      , 2003, 8(6):488-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/12791054/pubmed\" id=\"12791054\" target=\"_blank\">",
"        12791054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panisko DM and Keystone JS, &ldquo;Treatment of Malaria - 1990,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(2):160-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/2183998/pubmed\" id=\"2183998\" target=\"_blank\">",
"        2183998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations for the Prevention of Malaria Among Travelers,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1990, 39(RR-3):1-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulbe DE, &ldquo;Quinine Ban Signals Change for Pharmacists, APhA,&rdquo;",
"      <i>",
"       Pharmacy Today",
"      </i>",
"      , 1995, 1(12):6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vannier E and Krause PJ, &ldquo;Human Babesiosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(25):2397-2407.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/22716978/pubmed\" id=\"22716978\" target=\"_blank\">",
"        22716978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;The Treatment of Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(11):800-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/8703186/pubmed\" id=\"8703186\" target=\"_blank\">",
"        8703186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winek CL, Schweighardt FK, Fochtman FW, et al, &ldquo;Quinine in Urinanalysis for Heroin,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1971, 217(9):1243-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/5109466/pubmed\" id=\"5109466\" target=\"_blank\">",
"        5109466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(9):1089-134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/17029130/pubmed\" id=\"17029130\" target=\"_blank\">",
"        17029130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria Chemoprophylaxis for the Traveler,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/8505942/pubmed\" id=\"8505942\" target=\"_blank\">",
"        8505942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria: Overview and Update,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1993, 16(4):449-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/46/15080/abstract-text/8513046/pubmed\" id=\"8513046\" target=\"_blank\">",
"        8513046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9847 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15080=[""].join("\n");
var outline_f14_46_15080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9776905\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216572\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216592\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216575\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216585\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216576\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216577\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343960\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216550\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216535\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662364\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803185\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216554\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216588\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216599\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216590\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216557\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216539\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216586\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216544\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216568\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216547\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343867\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216580\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343869\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216559\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4380080\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554010\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038794\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216538\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216556\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/0/13317?source=related_link\">",
"      Quinine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=related_link\">",
"      Quinine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_46_15081="Treatment and prognosis of congenital hypothyroidism";
var content_f14_46_15081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of congenital hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Stephen LaFranchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15081/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/46/15081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hypothyroidism is one of the most common treatable causes of intellectual disability (mental retardation). Screening programs have been established in most developed countries to detect and treat this disorder, which affects approximately 1 in 2000 to 1 in 4000 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preterm infants have an immature hypothalamic-pituitary-thyroid axis, resulting in lower serum T4 levels as compared to term infants. Thus, in newborn screening programs that undertake a primary T4 test, infants born prematurely are more likely to have an abnormal thyroid screening test as compared to infants born at term. Interpretation of thyroid screening tests in preterm infants, and subsequent clinical decision-making are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40696?source=see_link\">",
"     \"Thyroid physiology and screening in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delays in diagnosis and treatment of congenital hypothyroidism will result in impaired neurocognitive outcome (as measured by intelligence quotient [IQ]). Even after diagnosis, IQ and neurologic development may suffer if the infant has hypothyroidism during the first two to three years of life, a time of critical brain dependence on thyroid hormone. Hypothyroidism in such infants may result from delayed detection and initiation of treatment after birth or from inadequate treatment during the first two to three years of life. Thus, appropriate initial therapy and follow-up are essential [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall goals of treatment are to assure normal growth and development and psychometric outcome similar to genetic potential, by restoring the serum T4 concentration rapidly to the normal range followed by continued clinical and biochemical euthyroidism.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (L-T4) is the treatment of choice. Although triiodothyronine (T3) is the more biologically active hormone, the majority of brain T3 is derived from local deiodination of T4; thus, it is not necessary to use T3. To correct hypothyroxinemia as rapidly as possible, treatment should be initiated in an infant with a clearly positive screening test as soon as confirmatory blood samples have been drawn, pending results. In cases in which screening tests are borderline, a treatment decision can be made after results of the confirmatory tests return [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and detection of congenital hypothyroidism\", section on 'Newborn screening programs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dose of L-T4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the timing and dose of thyroid hormone replacement are important [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) recommends a starting L-T4 dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"     4",
"    </a>",
"    ]. The initial goal of treatment should be to restore the serum T4 concentration to &gt;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (&gt;129",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or a serum free T4 (fT4) in the upper half of the normal range for age as rapidly as possible. In one small study, patients who took longer than two weeks to normalize their thyroid function had lower cognitive, attention, and achievement scores than those who achieved normal function within two weeks after therapy was started [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/5\">",
"     5",
"    </a>",
"    ]. In a literature review identifying 11 studies evaluating the age of onset of thyroid hormone treatment, infants started \"early\" (12 to 30 days of age) had a mean IQ 15.7 points higher than infants started \"later\" (&gt;30 days of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As expected, there is an inverse correlation between the starting L-T4 dose and the time to achieve the goal serum T4 concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/7\">",
"     7",
"    </a>",
"    ]. The recommended initial L-T4 dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day usually amounts to 37.5 or 50",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"     4",
"    </a>",
"    ]. However, in the above study, full-scale IQ scores were 11 points higher in those started on 50",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    versus 37.5",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, we recommend the higher L-T4 dose (50",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    in full-size term infants. In preterm and other low-birth weight infants, we recommend using 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day. For infants with low serum T4 levels (&le;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    or 65",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    we would recommend using a dose closer to the higher end of the initial AAP recommended dose (ie, 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day).",
"   </p>",
"   <p>",
"    Rapid replacement with adequate doses of L-T4 is particularly important in infants with severe hypothyroidism. This was illustrated in an observational study of 61 infants with congenital hypothyroidism who were treated early versus late (&lt; or &ge;13 days of age) with a high versus low starting dose of L-T4 (&ge; or &lt;9.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/8\">",
"     8",
"    </a>",
"    ]. In infants with more severe hypothyroidism, only those treated early with high-dose L-T4 achieved normal psychomotor development at 10 to 30 months. In infants with mild hypothyroidism, all achieved normal psychomotor development except for those treated late with a low starting dose. Re-evaluation of mental, psychomotor and behavioral development at 6 years of age found that global IQ was the same as control patients matched by age and socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/9\">",
"     9",
"    </a>",
"    ]. However, visuomotor and verbal test scores were lower in patients with congenital hypothyroidism compared with control children. Patients who were treated late with a low starting dose had much lower verbal scores compared with other patients with congenital hypothyroidism. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The feasibility and safety of tailoring the starting dose of L-T4 to severity of hypothyroidism was confirmed by a study in which infants with more severe hypothyroidism were given a higher initial L-T4 dose than those with milder hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/10\">",
"     10",
"    </a>",
"    ]. This approach rapidly normalized serum free T4 levels without producing persistent hyperthyroxinemia.",
"   </p>",
"   <p>",
"    Only L-T4 tablets should be used. There are currently no approved liquid preparations in the United States (although these are available in Europe), and thyroid suspensions prepared by individual pharmacists may result in unreliable dosing. The L-T4 tablet should be crushed, mixed with breast milk, formula, or water, and fed to the infant. The tablets should",
"    <strong>",
"     not",
"    </strong>",
"    be mixed with soy formulas or any preparation containing concentrated iron or calcium, both of which reduce the absorption of L-T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/11\">",
"     11",
"    </a>",
"    ]. Antacids (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    ) or infant &ldquo;colic&rdquo; drops (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/9/27795?source=see_link\">",
"     simethicone",
"    </a>",
"    ) also may interfere with L-T4 absorption, and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The absorption of L-T4 is somewhat reduced by administration with food and formula. However, requiring that L-T4 be given separately from meals may be difficult for the family and reduce compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, instead of requiring L-T4 administration on an empty stomach, we ask the family to be consistent in how they administer the medication, in both time of day and presence or absence of food. The L-T4 dose then can be adjusted based on serum free T4 (or T4) and thyroid-stimulating hormone (TSH) levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of soy protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have raised concern that soy protein may affect the absorption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolism of L-T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. As an example, TSH concentrations, L-T4 dose, and growth parameters were compared between eight infants with congenital hypothyroidism who were fed soy formula and 70 who were fed a non-soy diet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/15\">",
"     15",
"    </a>",
"    ]. Despite similar pretreatment TSH concentrations, after initiation of L-T4 therapy, infants fed a soy diet achieved normal TSH (&lt;10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    much more slowly (median of 150 versus 40 days in infants fed a non-soy diet). T4 concentrations and growth parameters were similar in both groups; measures of neuropsychological development were not available. Infants with congenital hypothyroidism in whom soy formula is indicated should be monitored closely with serum T4 and TSH, and the dose of L-T4 should be increased as necessary to achieve normal thyroid function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of treatment is to keep the serum T4 or fT4 concentration in the upper half of the normal range. In the first year of life, the serum T4 values should be 10 to 16",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (130 to 206",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Comparable recommendations for serum free T4 vary with the assay method used in the testing laboratory. For example, if the reference range for a specific free T4 assay method is 0.8 to 2.3",
"    <span class=\"nowrap\">",
"     ng/dL,",
"    </span>",
"    the aim of treatment would be to keep the serum free T4 between 1.4 and 2.3",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (18 to 30",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"     4",
"    </a>",
"    ]. The serum TSH concentration should be less than 5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    and optimally 0.5 to 2.0",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"   </p>",
"   <p>",
"    Infants",
"    who have serum T4 concentrations below 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (129",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in the first year of life, particularly if accompanied by serum TSH concentrations above 15",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    will have lower IQs than infants whose serum T4 concentrations are above 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (129",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, overtreatment also can lead to complications and should be avoided. Persistently high serum T4 concentrations for age, especially if above 16",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (206",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    may adversely affect the tempo of brain development [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/18\">",
"     18",
"    </a>",
"    ], result in disorders of temperament [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/19\">",
"     19",
"    </a>",
"    ] or attention span [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/20\">",
"     20",
"    </a>",
"    ], and cause premature craniosynostosis.",
"   </p>",
"   <p>",
"    In studies in which the starting dose of L-T4 was 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day, there were no harmful effects on linear growth or skeletal maturation in the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recommended follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation should be performed every few months during the first three years of life. Laboratory evaluation should be carried out more often to ensure optimal L-T4 dose. The American Academy of Pediatrics recommends measurement of serum T4 or fT4 and TSH according to the following schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At 2 and 4 weeks after the initiation of L-T4 treatment",
"     </li>",
"     <li>",
"      Every 1 to 2 months during the first 6 months of life",
"     </li>",
"     <li>",
"      Every 3 to 4 months between 6 months and 3 years of age",
"     </li>",
"     <li>",
"      Every 6 to 12 months thereafter until growth is complete",
"     </li>",
"     <li>",
"      Two weeks after any change in dose",
"     </li>",
"     <li>",
"      At more frequent intervals when compliance is questioned or abnormal results are obtained",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more frequent monitoring schedule than that outlined above may be advisable during infancy: one study found that monthly monitoring during the first year of life led to a dose adjustment in 75 percent of infants younger than six months, and in 36 percent of infants between 6 and 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/22\">",
"     22",
"    </a>",
"    ]. Based on this study and personal experience, we recommend revising the AAP schedule to monitoring every two to three months between six months and three years of age. Monitoring at these intervals should help avoid prolonged under- or over-treatment.",
"   </p>",
"   <p>",
"    The serum T4 concentration should become normal within one to two weeks, and serum TSH should be normal in most infants after one month of treatment. Some infants may have a high serum TSH concentration (10 to 20",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    despite serum T4 values in the upper half of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/23\">",
"     23",
"    </a>",
"    ]. Conversely, when serum TSH is normal, some infants will have elevated serum free T4 above the reference range for age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/24\">",
"     24",
"    </a>",
"    ]. This appears to be the result of resetting of the pituitary-thyroid feedback threshold because of intrauterine hypothyroidism. In a study of 42 patients with congenital hypothyroidism, this mild to moderate thyroid hormone resistance was more common in infants (less than one year of age) than in older children (43 versus 10 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/25\">",
"     25",
"    </a>",
"    ]. These data suggest the resistance improves with age, but can persist. Another study in older children with congenital hypothyroidism (mean age 7.1 years) and thyroid hormone resistance found that a combination of L-T4 and T3 treatment lowered high TSH levels into the normal range with concomitant normal serum T4 and T3 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/26\">",
"     26",
"    </a>",
"    ]. The benefits of such treatment are unclear; we do not recommend combination treatment, particularly in infants, until further studies are performed.",
"   </p>",
"   <p>",
"    While the United States Food and Drug Administration (FDA) considers all forms of L-T4 to be bioequivalent, a recent prospective, randomized crossover study concluded that generic and brand-name L-T4 are not bioequivalent for children with severe congenital hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/27\">",
"     27",
"    </a>",
"    ], while another retrospective study found no differences [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/28\">",
"     28",
"    </a>",
"    ]. Consequently, if an infant is switched from brand to generic, or from one brand to another brand, or one manufacturer of generic to another manufacturer of generic L-T4, we recommend checking serum TSH and free T4 after six weeks to determine if a dosing adjustment is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assessment of permanent versus transient hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with congenital hypothyroidism have transient hypothyroidism. A study of health insurance claims data (both privately insured and Medicaid-enrolled patients) in children diagnosed with congenital hypothyroidism found that 38 percent had discontinued thyroid hormone replacement after 36 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/29\">",
"     29",
"    </a>",
"    ]. While the reason for discontinuation of treatment was unknown, the speculation was that many of these patients had transient hypothyroidism. Transient hypothyroidism is more common in populations affected by iodine deficiency, and can also be caused by maternal autoimmune thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any of the following findings can provide evidence of permanent hypothyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radionuclide imaging",
"      <strong>",
"       and",
"      </strong>",
"      ultrasonography of the thyroid gland (if performed) showing ectopic thyroid gland or absent thyroid tissue, or studies confirming dyshormonogenesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical features and detection of congenital hypothyroidism\", section on 'Diagnostic studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A rise in the serum TSH concentration to above 20",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      after the first year of life in the setting of insufficient L-T4 replacement.",
"     </li>",
"     <li>",
"      If permanent hypothyroidism has not been established by one of the above findings, L-T4 therapy can be discontinued for 30 days after age 3 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"       4",
"      </a>",
"      ]. If a low serum T4 or free T4 and high TSH concentration are found, permanent hypothyroidism is confirmed and treatment should be restarted. If the serum T4 or fT4 and TSH values remain normal, transient hypothyroidism is presumed. These children should still be examined periodically, and if they have any suspicious clinical features of hypothyroidism, such as slowing of growth, laboratory assessment of thyroid status should be performed. If the results are inconclusive, careful follow-up and subsequent retesting are indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The radionucleotide imaging and thyroid ultrasonography described above are considered optional because in most cases the results are not required for management decisions. However, some clinicians elect to perform these studies routinely. In a report of 33 children with congenital hypothyroidism who underwent imaging studies and were investigated at three years of age, 27 percent had an absent or ectopic thyroid, 36 percent had dyshormonogenesis, and 36 percent had transient hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/32\">",
"     32",
"    </a>",
"    ]. The percentage with transient hypothyroidism was higher than in other studies. The average dose of L-T4 at the time of discontinuation was lower among children with transient hypothyroidism than those with permanent hypothyroidism (2.0 versus 2.9",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel approach of potential utility is the use of recombinant human TSH (rhTSH) followed by scintigraphy to make the diagnosis of congenital hypothyroidism without requiring withdrawal of thyroid hormone therapy. In one study of eight patients with congenital hypothyroidism, scintigraphy was performed after rhTSH administration (0.6",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    on two consecutive days) while on L-T4 treatment at age 5 to 15 years, and the results were compared to scintigraphy that had been performed after thyroid hormone withdrawal and resulting TSH elevation in the same children at age three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/33\">",
"     33",
"    </a>",
"    ]. For all eight children, the scintigraphic findings after rhTSH administration were identical to those following thyroid hormone withdrawal, confirming permanent congenital hypothyroidism. However, use of rTSH for diagnostic purposes is expensive and not standard-of-care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Long-term management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom congenital hypothyroidism proves to be permanent (about 80 to 90 percent of cases of congenital hypothyroidism in North America) will require thyroid hormone replacement throughout life. These patients are managed by titrating L-T4 dose based on periodic measurements of serum TSH and free T4 or T4, as for an adolescent or adult with acquired hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link&amp;anchor=H22#H22\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'T4 dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several programs in North America, Europe, and Australia have now reported long-term follow-up of infants detected through newborn screening. In general, these infants grow and develop normally. The psychometric outcome is much improved over the prescreening era, but some severely affected infants or those who are inadequately treated in the first two or three years of life have IQs below those of normal children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Growth and cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up of children with congenital hypothyroidism detected by newborn screening shows that treated children have normal growth patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/34\">",
"     34",
"    </a>",
"    ] and normal adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/35\">",
"     35",
"    </a>",
"    ]. Moreover, a study comparing high vs. low initial doses of L-T4 did not show any untoward effect of the higher dose on linear growth up to 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other series have suggested possible metabolic abnormalities in children with treated hypothyroidism: a study from Switzerland reported an increased risk for overweight at age five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/37\">",
"     37",
"    </a>",
"    ]. Another study investigating cardiac function in young adults with congenital hypothyroidism reported left ventricular diastolic dysfunction, impaired exercise capacity, and increased intima-media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/38\">",
"     38",
"    </a>",
"    ]. The significance of these findings is unknown; they need to be confirmed by other investigators.",
"   </p>",
"   <p>",
"    A national population-based study from France reported a slightly higher all-cause mortality (standardized mortality ratio [SMR] = 1.24) in patients with congenital hypothyroidism diagnosed in the first decade of newborn screening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/39\">",
"     39",
"    </a>",
"    ]. SMR was highest for diseases of the central nervous system (SMR 5.22) and congenital malformations (SMR 3.15). In addition, the risk of developing an associated chronic disease was twice as high as the reference population. Clinicians caring for patients with congenital hypothyroidism should be aware of the potential for associated co-morbidities, primarily neurologic, mental illness, or related to congenital malformations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychometric outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, infants treated early (two to six weeks of life) and appropriately through the first three years of life have global IQs similar to normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. As an example, the New England Congenital Hypothyroidism Collaborative reported a verbal intelligence quotient (IQ) score of 109, a performance IQ score of 107, and a full scale IQ score of 109 at six years, essentially identical to a sibling and classmate control group [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/40\">",
"     40",
"    </a>",
"    ]. In a summary of psychometric testing from 10 screening programs of children ranging from 4 to 12 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/41\">",
"     41",
"    </a>",
"    ], six reported no difference in global IQ score compared with the control group, but four reported a reduction in IQ score ranging from 6 to 15 points.",
"   </p>",
"   <p>",
"    Even when there are no differences in global IQ scores, there may be differences in subtest components. A screening program in Toronto reported language deficits at age three years, which diminished with age, along with poor visual-spatial and verbal skills at age five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of low versus high starting L-T4 dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In long-term follow-up studies, 49 patients with congenital hypothyroidism diagnosed through the Norwegian neonatal screening program were compared with 41 sibling controls at 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Patients were divided into two groups based on their L-T4 starting dose: low dose group (&lt;7.8",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) and high dose (&ge;7.8",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day). The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with sibling controls, subjects had lower total, verbal, and performance IQ scores (total IQ 102.4 versus 111.4) as well as impaired arithmetic skills and naming in school-associated tests [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/45\">",
"       45",
"      </a>",
"      ]. In treated patients, higher initial L-T4 dose and mean serum T4 levels increased verbal IQ scores and arithmetic screening skills.",
"     </li>",
"     <li>",
"      Treated patients also had deficits in memory, attention, and behavior compared to their sibling controls [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/46\">",
"       46",
"      </a>",
"      ]. In contrast to the findings from a previous study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/47\">",
"       47",
"      </a>",
"      ], there was no difference between patients treated with high dose versus low dose thyroxine in memory testing and behavior problems when evaluated at 20 years of age. There was a suggestion that patients treated with high dose thyroxine were less distractible than those treated with the lower dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of ten studies described the effect of different starting L-T4 doses on psychometric outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/6\">",
"     6",
"    </a>",
"    ]. Two of the studies reported no effect, while six reported that lower starting doses resulted in lower IQ outcome, averaging 12.3 points. Of note, two studies reported that lower starting doses led to a better IQ outcome, averaging 8.6 points, as compared to higher doses. The preponderance of studies found that children treated with the currently recommended starting dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    have a better IQ outcome than children started on lower doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A long-term follow-up study from Switzerland assessed intellectual outcome of 63 patients at 14 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/48\">",
"     48",
"    </a>",
"    ]. Despite starting treatment at a mean of nine days of age with a median L-T4 dose of 14.7",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day, mean IQ was significantly lower in patients than in controls (101.7 vs. 111.4). Those adolescents with thyroid agenesis and lower socioeconomic status were at particular risk for adverse outcome.",
"   </p>",
"   <p>",
"    An even longer-term follow-up study from the Netherlands of 70 patients tested at 21.5 years of age found worse motor scores and IQ scores (full scale IQ 95.8, verbal IQ 96.4, performance IQ 95.6) as compared with healthy controls. The deficit was proportional to the initial degree of hypothyroidism and not the starting day of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/49\">",
"     49",
"    </a>",
"    ]. A second report from the same group also found impaired health related quality of life, lower self-esteem, and delayed social development when these patients were tested at 21.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/50\">",
"     50",
"    </a>",
"    ]. A similar long-term follow-up study from France of adults at 23.4 years of age also found a lower health-related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/51\">",
"     51",
"    </a>",
"    ]. Subjects were more likely to still be living with their parents and less likely to secure full-time employment. These adults were born in the first years of their respective screening programs and were started on treatment at a later age. As most infants are now started at an earlier age and treated with higher L-T4 doses, future results may be better.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Severely affected infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some screening programs report that more severely affected infants, as judged by a lower serum T4 concentration or immature skeletal maturation at diagnosis, have lower IQ scores later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/52\">",
"     52",
"    </a>",
"    ]. In a follow-up study at 12 years of age, for example, the Quebec screening network found that those infants with initial serum T4 values below 2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (26",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and a bone surface area less than 0.05 cm2 had a mean IQ score of 89, as compared with 104 in less severely affected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a literature review of 30 studies comparing psychometric outcome in infants with more severe versus moderate or mild congenital hypothyroidism, nine studies reported no difference in IQ, while 21 studies reported a 5.5- to 23-point decrease in IQ in the more severely affected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lower serum T4 values during the first years",
"    </span>",
"    &nbsp;&mdash;&nbsp;The New England Congenital Hypothyroidism Collaborative reported that a subgroup of 18 infants who were judged to be inadequately treated in the first three years of life (L-T4 dose &lt;5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) because of poor compliance had a mean serum T4 concentration of 8.6",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (112",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and an IQ score of 87, as compared with the larger, adequately treated group who had a mean serum T4 concentration of 11.2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (146",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and an IQ score of 105 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other neurologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of infants, including those with normal IQ scores, can have other neurologic problems, such as gross and fine motor incoordination, ataxia, increased or decreased muscle tone, short attention span, speech defects, and strabismus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/54\">",
"     54",
"    </a>",
"    ]. Studies before the initiation of newborn screening reported that up to 20 percent of children had sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the previously mentioned long-term follow-up studies, 49 patients with congenital hypothyroidism diagnosed through the Norwegian neonatal screening program were compared with 41 sibling controls at 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/45\">",
"     45",
"    </a>",
"    ]. Compared to controls, subjects had impaired motor coordination and global motor efficiency. Motor impairment was associated with severity of congenital hypothyroidism (pretreatment serum T4 concentration), but not with treatment variables, suggesting an irreversible prenatal effect on motor function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Effect of noncompliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The New England Collaborative found that noncompliance beyond the first three years of life can affect cognitive performance. When blood was drawn without forewarning at home visits from a group of 14 year-old adolescents with congenital hypothyroidism, 44 percent were poorly controlled as judged by a serum thyroid-stimulating hormone (TSH) concentration above 15",
"    <span class=\"nowrap\">",
"     mU/L;",
"    </span>",
"    serum T4 concentrations were low (&lt;6.6",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [86",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    in the majority [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/56\">",
"     56",
"    </a>",
"    ]. Psychometric tests were performed, compliance was stressed, and serum thyroid hormone concentrations were normal a year later. Repeat psychometric testing showed that this improvement was associated with a significant increase in IQ score from 106 to 112.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Maternal hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic development may be adversely affected in children born to mothers with hypothyroidism, even in the absence of neonatal hypothyroidism.",
"   </p>",
"   <p>",
"    One study identified 62 women who had hypothyroidism during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/57\">",
"     57",
"    </a>",
"    ]. Their children, when tested at age 7 to 9 years, had a mean IQ score of 103, as compared with a score of 107 in 124 children of mothers who were euthyroid during pregnancy. In addition, the children whose mothers were hypothyroid had more school learning problems or had more frequently repeated a grade compared to those with mothers who were euthyroid.",
"   </p>",
"   <p>",
"    Other studies have reported that low maternal serum T4 values early in pregnancy are associated with adverse neurodevelopmental outcomes in the offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. This was illustrated in a study that evaluated the mental and motor functions of 63 infants whose mothers had serum free T4 values (fT4) below the 10th percentile (fT4 concentration &lt;0.94",
"    <span class=\"nowrap\">",
"     ng/dL,",
"    </span>",
"    [&lt;12.4",
"    <span class=\"nowrap\">",
"     pmol/L])",
"    </span>",
"    during the 12th week of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/59\">",
"     59",
"    </a>",
"    ]. In these infants, both motor and mental functions (evaluated by Bayley Scales of Infant Development) were delayed at one and two years of age compared with infants whose mothers had fT4 values between the 50th and 90th percentile (fT4 concentration between 1.21 and 1.48",
"    <span class=\"nowrap\">",
"     ng/dl",
"    </span>",
"    [15.6 and 19.1",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    levels]). In a subsequent study of 108 infants born to mothers with low maternal fT4 levels at 12 weeks gestation, infants had a lower score on the Neonatal Behavioral Assessment Scale (NBAS) \"orientation index\" at three weeks of age compared with infants with higher maternal fT4 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/60\">",
"     60",
"    </a>",
"    ]. It should be noted that the \"orientation index\" was only one of seven NBAS \"cluster scores\" that achieved statistical significance. In observing neurodevelopmental outcomes soon after birth, this study avoids many possible confounding factors that may alter developmental outcomes when these are evaluated later in life. Furthermore, in a population-based cohort study from the Netherlands of 3659 children and their mothers, mild maternal hypothyroxinemia at 13 weeks gestation was associated with a higher risk of expressive language delay in the offspring, and a severe maternal hypothyroxinemia was associated with a higher risk of nonverbal cognitive delay [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a more recent study, 21,846 women from the United Kingdom and Italy underwent thyroid testing at 12 weeks of gestation. Those with a TSH &gt;97.5",
"    <sup>",
"     th",
"    </sup>",
"    percentile or a free T4 &lt;2.5",
"    <sup>",
"     th",
"    </sup>",
"    percentile were randomized to thyroid hormone treatment or observation. At age three years, mean IQ of the offspring was 99.2 in the treated and 100 in the control group. The investigators concluded that there was no adverse effect of maternal hypothyroidism on cognitive function in the offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/62\">",
"     62",
"    </a>",
"    ]. It should be noted that these women appeared to have milder hypothyroidism than those in the other studies cited above.",
"   </p>",
"   <p>",
"    These studies suggest that low maternal serum T4 concentrations early in pregnancy (before the time the fetus begins to produce its own T4) may be a risk factor for impaired infant development. In a consensus statement, the American Thyroid Association (ATA) recommends that women who are at risk for thyroid disease based on personal or family history, symptoms or physical examination findings, or a history of other autoimmune disorders should undergo thyroid testing early in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15081/abstract/63\">",
"     63",
"    </a>",
"    ]. The ATA does not recommend universal maternal screening of thyroid function during pregnancy.",
"   </p>",
"   <p>",
"    There is some evidence that maternal anti-thyroid antibodies also may have some effects on fetal development and miscarriage rates even if the mother is euthyroid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid peroxidase antibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology of hearing impairment in children\", section on 'Congenital'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/34/27170?source=see_link\">",
"       \"Patient information: Congenital hypothyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19859153\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prompt identification and treatment of infants with congenital hypothyroidism is essential to assure normal growth and cognitive development. Treatment should be initiated in an infant with a clearly positive screening test as soon as confirmatory blood samples have been drawn, pending results. In cases in which screening tests are borderline, a treatment decision can be made after results of the confirmatory tests become available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Infants with suspected congenital hypothyroidism should be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"       levothyroxine",
"      </a>",
"      (L-T4) by mouth, starting at a dose of 10 to 15",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day. We suggest tailoring the starting L-T4 dose to the severity of hypothyroidism, using doses on the upper end of this range (usually 50",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      in full-sized term infants) for neonates with more severe hypothyroidism (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dose of L-T4'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aim of treatment is to keep the serum T4 or free T4 concentration in the upper half of the normal range. Target values during the first year of life are: (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment goals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum T4: 10 to 16",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (130 to 206",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum free T4: target varies with the assay method; for example, if the normal reference range is 0.8 to 2.3",
"      <span class=\"nowrap\">",
"       ng/dL,",
"      </span>",
"      aim for 1.4 to 2.3",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (18 to 30",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Serum thyroid-stimulating hormone (TSH): 0.5 to 5",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and children should be monitored closely during treatment, and the L-T4 dose adjusted to maintain serum T4 or free T4 and TSH levels in the target ranges. Monitoring is important to avoid prolonged under- or over-treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommended follow-up'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Up to 30 percent of children with congenital hypothyroidism have a transient form and will regain normal endogenous thyroid function during early life. Therefore, thyroid function should be retested around three years of age to determine whether the hypothyroidism is permanent or transient. In most cases, this is done by discontinuing therapy for 30 days and monitoring thyroid hormones. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Assessment of permanent versus transient hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants with congenital hypothyroidism who are treated early (treatment begun between two and six weeks of life) and appropriately treated through the first three years of life, the prognosis for mental and physical development is good. The prognosis worsens for infants who are detected later, have more severe hypothyroidism,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who receive inadequate doses of L-T4. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Long-term outcomes'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/1\">",
"      Rastogi MV, LaFranchi SH. Congenital hypothyroidism. Orphanet J Rare Dis 2010; 5:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/2\">",
"      Gr&uuml;ters A, Krude H. Detection and treatment of congenital hypothyroidism. Nat Rev Endocrinol 2012; 8:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/3\">",
"      LaFranchi SH. Approach to the diagnosis and treatment of neonatal hypothyroidism. J Clin Endocrinol Metab 2011; 96:2959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/4\">",
"      American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006; 117:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/5\">",
"      Selva KA, Harper A, Downs A, et al. Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. J Pediatr 2005; 147:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/6\">",
"      LaFranchi SH, Austin J. How should we be treating children with congenital hypothyroidism? J Pediatr Endocrinol Metab 2007; 20:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/7\">",
"      Germak JA, Foley TP Jr. Longitudinal assessment of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1990; 117:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/8\">",
"      Bongers-Schokking JJ, Koot HM, Wiersma D, et al. Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism. J Pediatr 2000; 136:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/9\">",
"      Bongers-Schokking JJ, de Muinck Keizer-Schrama SM. Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism. J Pediatr 2005; 147:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/10\">",
"      Mathai S, Cutfield WS, Gunn AJ, et al. A novel therapeutic paradigm to treat congenital hypothyroidism. Clin Endocrinol (Oxf) 2008; 69:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/11\">",
"      Jabbar MA, Larrea J, Shaw RA. Abnormal thyroid function tests in infants with congenital hypothyroidism: the influence of soy-based formula. J Am Coll Nutr 1997; 16:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/12\">",
"      Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child 2011; 96:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/13\">",
"      Zeitler P, Solberg P, Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Food and levothyroxine administration in infants and children. J Pediatr 2010; 157:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/14\">",
"      Chorazy PA, Himelhoch S, Hopwood NJ, et al. Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature. Pediatrics 1995; 96:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/15\">",
"      Conrad SC, Chiu H, Silverman BL. Soy formula complicates management of congenital hypothyroidism. Arch Dis Child 2004; 89:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/16\">",
"      Characteristics of infantile hypothyroidism discovered on neonatal screening. J Pediatr 1984; 104:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/17\">",
"      Heyerdahl S, Kase BF, Lie SO. Intellectual development in children with congenital hypothyroidism in relation to recommended thyroxine treatment. J Pediatr 1991; 118:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/18\">",
"      Weichsel ME Jr. Thyroid hormone replacement therapy in the perinatal period: neurologic considerations. J Pediatr 1978; 92:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/19\">",
"      Rovet JF, Ehrlich RM, Sorbara DL. Effect of thyroid hormone level on temperament in infants with congenital hypothyroidism detected by screening of neonates. J Pediatr 1989; 114:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/20\">",
"      Rovet J, Alvarez M. Thyroid hormone and attention in congenital hypothyroidism. J Pediatr Endocrinol Metab 1996; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/21\">",
"      Fisher DA, Foley BL. Early treatment of congenital hypothyroidism. Pediatrics 1989; 83:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/22\">",
"      Balhara B, Misra M, Levitsky LL. Clinical monitoring guidelines for congenital hypothyroidism: laboratory outcome data in the first year of life. J Pediatr 2011; 158:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/23\">",
"      Eldar D, Kaiserman I, Sack J. Early identification of congenital hypothyroid infants with abnormalities in pituitary setpoint for T4-induced TSH release. Horm Res 1993; 40:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/24\">",
"      Kempers MJ, van Trotsenburg AS, van Tijn DA, et al. Disturbance of the fetal thyroid hormone state has long-term consequences for treatment of thyroidal and central congenital hypothyroidism. J Clin Endocrinol Metab 2005; 90:4094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/25\">",
"      Fisher DA, Schoen EJ, La Franchi S, et al. The hypothalamic-pituitary-thyroid negative feedback control axis in children with treated congenital hypothyroidism. J Clin Endocrinol Metab 2000; 85:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/26\">",
"      Akcay T, Turan S, Guran T, et al. T4 plus T3 treatment in children with hypothyroidism and inappropriately elevated thyroid-stimulating hormone despite euthyroidism on T4 treatment. Horm Res Paediatr 2010; 73:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/27\">",
"      Carswell JM, Gordon JH, Popovsky E, et al. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. J Clin Endocrinol Metab 2013; 98:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/28\">",
"      Lomenick JP, Wang L, Ampah SB, et al. Generic levothyroxine compared with synthroid in young children with congenital hypothyroidism. J Clin Endocrinol Metab 2013; 98:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/29\">",
"      Kemper AR, Ouyang L, Grosse SD. Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. BMC Pediatr 2010; 10:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/30\">",
"      Delange F, Dalhem A, Bourdoux P, et al. Increased risk of primary hypothyroidism in preterm infants. J Pediatr 1984; 105:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/31\">",
"      Pacaud D, Huot C, Gattereau A, et al. Outcome in three siblings with antibody-mediated transient congenital hypothyroidism. J Pediatr 1995; 127:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/32\">",
"      Eugster EA, LeMay D, Zerin JM, Pescovitz OH. Definitive diagnosis in children with congenital hypothyroidism. J Pediatr 2004; 144:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/33\">",
"      Tiosano D, Even L, Shen Orr Z, Hochberg Z. Recombinant thyrotropin in the diagnosis of congenital hypothyroidism. J Clin Endocrinol Metab 2007; 92:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/34\">",
"      Aronson R, Ehrlich RM, Bailey JD, Rovet JF. Growth in children with congenital hypothyroidism detected by neonatal screening. J Pediatr 1990; 116:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/35\">",
"      Delvecchio M, Salerno M, Acquafredda A, et al. Factors predicting final height in early treated congenital hypothyroid patients. Clin Endocrinol (Oxf) 2006; 65:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/36\">",
"      Jones JH, Gell&eacute;n B, Paterson WF, et al. Effect of high versus low initial doses of L-thyroxine for congenital hypothyroidism on thyroid function and somatic growth. Arch Dis Child 2008; 93:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/37\">",
"      Arenz S, Nennstiel-Ratzel U, Wildner M, et al. Intellectual outcome, motor skills and BMI of children with congenital hypothyroidism: a population-based study. Acta Paediatr 2008; 97:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/38\">",
"      Salerno M, Oliviero U, Lettiero T, et al. Long-term cardiovascular effects of levothyroxine therapy in young adults with congenital hypothyroidism. J Clin Endocrinol Metab 2008; 93:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/39\">",
"      Azar-Kolakez A, Ecosse E, Dos Santos S, L&eacute;ger J. All-cause and disease-specific mortality and morbidity in patients with congenital hypothyroidism treated since the neonatal period: a national population-based study. J Clin Endocrinol Metab 2013; 98:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/40\">",
"      Neonatal hypothyroidism screening: status of patients at 6 years of age. New England Congenital Hypothyroidism Collaborative. J Pediatr 1985; 107:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/41\">",
"      Grant DB, Fuggle P, Tokar S, Smith I. Psychomotor development in infants with congenital hypothyroidism diagnosed by neonatal screening. Acta Med Austriaca 1992; 19 Suppl 1:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/42\">",
"      Rovet JF. Children with congenital hypothyroidism and their siblings: do they really differ? Pediatrics 2005; 115:e52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/43\">",
"      Derksen-Lubsen G, Verkerk PH. Neuropsychologic development in early treated congenital hypothyroidism: analysis of literature data. Pediatr Res 1996; 39:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/44\">",
"      Rovet JF, Ehrlich RM, Sorbara DL. Neurodevelopment in infants and preschool children with congenital hypothyroidism: etiological and treatment factors affecting outcome. J Pediatr Psychol 1992; 17:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/45\">",
"      Oerbeck B, Sundet K, Kase BF, Heyerdahl S. Congenital hypothyroidism: influence of disease severity and L-thyroxine treatment on intellectual, motor, and school-associated outcomes in young adults. Pediatrics 2003; 112:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/46\">",
"      Oerbeck B, Sundet K, Kase BF, Heyerdahl S. Congenital hypothyroidism: no adverse effects of high dose thyroxine treatment on adult memory, attention, and behaviour. Arch Dis Child 2005; 90:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/47\">",
"      Rovet JF, Ehrlich RM. Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1995; 126:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/48\">",
"      Dimitropoulos A, Molinari L, Etter K, et al. Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment. Pediatr Res 2009; 65:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/49\">",
"      Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden MW, et al. Intellectual and motor development of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 2006; 91:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/50\">",
"      van der Sluijs Veer L, Kempers MJ, Last BF, et al. Quality of life, developmental milestones, and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 2008; 93:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/51\">",
"      L&eacute;ger J, Ecosse E, Roussey M, et al. Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study. J Clin Endocrinol Metab 2011; 96:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/52\">",
"      Tillotson SL, Fuggle PW, Smith I, et al. Relation between biochemical severity and intelligence in early treated congenital hypothyroidism: a threshold effect. BMJ 1994; 309:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/53\">",
"      Glorieux J, Dussault J, Van Vliet G. Intellectual development at age 12 years of children with congenital hypothyroidism diagnosed by neonatal screening. J Pediatr 1992; 121:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/54\">",
"      Dattani M, Brook CG. Outcomes of neonatal screening for congenital hypothyroidism. Curr Opin Pediatr 1996; 8:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/55\">",
"      Bellman SC, Davies A, Fuggle PW, et al. Mild impairment of neuro-otological function in early treated congenital hypothyroidism. Arch Dis Child 1996; 74:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/56\">",
"      Correlation of cognitive test scores and adequacy of treatment in adolescents with congenital hypothyroidism. New England Congenital Hypothyroidism Collaborative. J Pediatr 1994; 124:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/57\">",
"      Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/58\">",
"      Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 1999; 50:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/59\">",
"      Pop VJ, Brouwers EP, Vader HL, et al. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. Clin Endocrinol (Oxf) 2003; 59:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/60\">",
"      Kooistra L, Crawford S, van Baar AL, et al. Neonatal effects of maternal hypothyroxinemia during early pregnancy. Pediatrics 2006; 117:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/61\">",
"      Henrichs J, Bongers-Schokking JJ, Schenk JJ, et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. J Clin Endocrinol Metab 2010; 95:4227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/62\">",
"      Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012; 366:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15081/abstract/63\">",
"      American Thyroid Association. Consensus Statement #2: American Thyroid Association statement on early maternal thyroidal insufficiency: recognition, clinical management and research directions. Thyroid 2005; 15:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5837 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15081=[""].join("\n");
var outline_f14_46_15081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19859153\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dose of L-T4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of soy protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recommended follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assessment of permanent versus transient hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Long-term management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Growth and cardiac function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychometric outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of low versus high starting L-T4 dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Severely affected infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lower serum T4 values during the first years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other neurologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Effect of noncompliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Maternal hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19859153\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/34/27170?source=related_link\">",
"      Patient information: Congenital hypothyroidism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40696?source=related_link\">",
"      Thyroid physiology and screening in preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_46_15082="Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis";
var content_f14_46_15082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Bhoomi Mehrotra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/46/15082/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/46/15082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallbladder cancer (GBC) is an uncommon but highly fatal malignancy; fewer than 5000 new cases are diagnosed each year in the United States. The majority are found incidentally in patients undergoing exploration for cholelithiasis; a tumor will be found in 1 to 2 percent of such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The poor prognosis associated with GBC is thought to be related to advanced stage at diagnosis, which is due both to the anatomic position of the gallbladder, and the vagueness and nonspecificity of symptoms.",
"   </p>",
"   <p>",
"    Here we will discuss the epidemiology, risk factors, clinical features, and diagnostic evaluation of GBC. Treatment of localized, potentially resectable GBC, and treatment for advanced disease are covered separately, as is cholangiocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43399?source=see_link\">",
"     \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33977?source=see_link\">",
"     \"Treatment of advanced, unresectable gallbladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, there is a prominent geographic variability in GBC incidence that correlates with the prevalence of cholelithiasis. High rates of GBC are seen in South American countries, particularly Chile, Bolivia, and Ecuador, as well as some areas of India, Pakistan, Japan and Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In Chile, mortality rates from GBC are the highest in the world. These populations all share a high prevalence of gallstones",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    salmonella infection, both recognized risk factors for GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Both genetic factors and socioeconomic issues that delay or prevent access to cholecystectomy for gallstones are thought to be contributory [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    North America is considered a low incidence area. In the United States, GBC is the most common cancer arising in the biliary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/1\">",
"     1",
"    </a>",
"    ]. Estimates from the SEER (Surveillance, Epidemiology and End Results) database reveal an incidence of 1 to 2 cases per 100,000 population in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the available data support a decreased overall incidence of GBC in the United States over the last 30 years, the incidence may be increasing in younger individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In contrast to the general population, GBC is the most common GI malignancy in both Southwestern Native Americans and in Mexican Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to geography, there are also age, race, and gender-related differences in the incidence of GBC. Incidence steadily increases with age, women are affected two to six times more often than men [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], and GBC is more common in Caucasians than in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors have been identified for GBC, many of which share a common characteristic of chronic gallbladder inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/5,14,18-20\">",
"     5,14,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gallstone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstones are present in 70 to 90 percent of patients with GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/19,21\">",
"     19,21",
"    </a>",
"    ], and a history of gallstones appears to be one of the strongest risk factors for the development of GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/6,19,20,22-24\">",
"     6,19,20,22-24",
"    </a>",
"    ]. As an example, in a case-control study from Shanghai that included 368 patients with GBC and 959 healthy controls, individuals with symptomatic gallbladder disease (gallstones or self-reported cholecystitis) were 34-fold more likely to develop GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the increased risk of GBC in patients with gallstones, the overall incidence of GBC in patients with cholelithiasis is only 0.5 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk is higher with larger gallstones (in one study, patients with stones larger than 3 cm had a 10-fold higher risk of GBC compared to those with stones &lt;1 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/25\">",
"     25",
"    </a>",
"    ]) and longer duration of cholelithiasis (particularly over 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/26\">",
"     26",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Porcelain gallbladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porcelain gallbladder is an uncommon manifestation of chronic cholecystitis that is characterized by intramural calcification of the gallbladder wall. It is associated with cholelithiasis in more than 95 percent of cases. As with other gallstone-related conditions, these patients are at increased risk of GBC. The reported incidence of GBC in patients with a porcelain gallbladder ranges from 0 to 60 percent, with more recent studies suggesting a rate of approximately 2 to 3 percent. The increased risk may be confined to patients with selective mucosal calcification or incomplete mural calcification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39668?source=see_link&amp;anchor=H2#H2\">",
"     \"Porcelain gallbladder\", section on 'Epidemiology and risk of malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gallbladder polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallbladder polyps are outgrowths of the gallbladder mucosal wall that are usually found incidentally on ultrasonography or after cholecystectomy. They are classified as benign or malignant, and benign lesions are further classified as nonneoplastic (eg, cholesterol and inflammatory polyps, adenomyomas) or neoplastic (eg, adenomas, leiomyomas) (",
"    <a class=\"graphic graphic_table graphicRef56347 \" href=\"UTD.htm?39/17/40219\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common benign neoplastic lesion is an adenoma, a glandular tumor composed of cells resembling biliary tract epithelium. It is unclear whether adenomatous polyps represent a premalignant lesion and if so, the frequency with which they progress to carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/27\">",
"     27",
"    </a>",
"    ]. Unlike GBC, gallbladder polyps tend not to occur in patients with cholelithiasis, chronic inflammation is generally absent, and cancer-related molecular changes that are seen in GBCs have not been identified in adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, larger polyps are more likely to contain foci of invasive cancer, and some studies suggest a correlation between the presence of gallbladder polyps and the risk of GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=see_link\">",
"     \"Gallbladder polyps and cholesterolosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Salmonella",
"    </span>",
"    &nbsp;&mdash;&nbsp;In endemic settings, approximately 1 to 4 percent of acutely infected individuals become chronic asymptomatic carriers of salmonella typhi (S. typhi). Several reports suggest an association between chronic S. typhi carriage and elevated risk of GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. A prospective case control study of patients with carcinoma of the gallbladder and gallstones (cases) or gallstones alone (controls) identified the S. typhi carrier state as an independent risk factor for carcinoma of the gallbladder (OR=14) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/29\">",
"     29",
"    </a>",
"    ]. Because chronic carriage occurs more often in individuals with cholelithiasis, gallstones are thought to represent a potential nidus for ongoing infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of typhoid fever\", section on 'Chronic carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Helicobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helicobacter colonization of the biliary epithelium (particularly H. bilis) has been implicated in the pathogenesis of gallbladder disease including gallbladder cancer based upon detection of Helicobacter-derived cytotoxins and surface proteins using sensitive molecular and immunohistochemical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. The strength of this association requires further clarification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Congenital biliary cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary cysts are cystic dilatations which may occur singly or in multiples throughout the bile ducts. They were originally termed choledochal cysts (involving the extrahepatic bile duct), but the clinical classification was revised in 1977 to include intrahepatic cysts. Biliary cysts may be congenital or acquired, and they are associated with a variety of anatomic abnormalities. An anomalous pancreaticobiliary duct junction is present in about 70 percent of patients with biliary cysts (see below). Like anomalous pancreaticobiliary duct junction, biliary cysts are especially frequent in Asian populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link\">",
"     \"Biliary cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biliary cysts are associated with an increased risk of cancer, particularly cholangiocarcinoma. The incidence of malignancy varies with age. In a 1983 review of all published series of biliary cysts, the incidence of cancer was 0.7 percent in patients under 10 years of age, 6.8 percent in patients 11 to 20 years of age, and 14.3 percent in patients over 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/37\">",
"     37",
"    </a>",
"    ]. An incidence as high as 50 percent has been reported in older patients. At least one study suggests that the increased incidence of carcinoma in biliary cysts is confined to patients with an anomalous pancreaticobiliary duct junction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link&amp;anchor=H9#H9\">",
"     \"Biliary cysts\", section on 'Cancer risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Abnormal pancreaticobiliary duct junction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anomalous pancreaticobiliary duct junction is a rare anatomic variation in which the pancreatic duct drains into the common bile duct, resulting in a long common channel (usually over 2 cm in length). This condition may represent failure of the embryological ducts to migrate fully into the duodenum. This condition is most prevalent in Asians populations, mostly Japanese [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long common channel may predispose to reflux of pancreatic juice into the biliary tree, since the ductal junction lies outside of the sphincter of Oddi. Elevated sphincter of Oddi pressures have been documented in anomalous pancreaticobiliary duct junction and could also promote pancreaticobiliary reflux. The result is increased amylase levels in bile, intraductal activation of proteolytic enzymes, alterations in bile composition, and presumed biliary epithelial damage, inflammation, ductal distension, and cyst formation.",
"   </p>",
"   <p>",
"    Anomalous pancreaticobiliary duct junction appears to increase the risk of biliary and pancreatic malignancy even in patients without a biliary cyst or ductal dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Gallbladder cancer is the most common malignancy seen in patients with anomalous pancreaticobiliary duct junction and no bile duct cyst. As a result, prophylactic cholecystectomy is recommended in affected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link&amp;anchor=H5#H5\">",
"     \"Biliary cysts\", section on 'Role of an abnormal pancreaticobiliary junction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular pathogenesis of GBC arising in patients with an anomalous pancreaticobiliary duct junction appears to be different from that underlying the development of GBC in the setting of gallstone disease. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some drugs have also been implicated in biliary carcinogenesis, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    , oral contraceptives, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Others have found no convincing evidence for an association between oral contraceptive use and GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carcinogen exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence is accumulating that carcinogen exposure may also be involved in the etiology of GBC. An increased risk of GBC has been described in workers in the oil, paper, chemical, shoe, textile, and cellulose acetate fiber manufacturing industries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/7,51\">",
"     7,51",
"    </a>",
"    ], and in miners exposed to radon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/52\">",
"     52",
"    </a>",
"    ]. An increased risk has also been noted in cigarette smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has been consistently associated with an increased risk for GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/22,54-57\">",
"     22,54-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link&amp;anchor=H28#H28\">",
"     \"Health hazards associated with obesity in adults\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588275136\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports suggest a modest association between diabetes and risk for GBC, but the relationship may be in part mediated by obesity and a higher risk of gallstones in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/53,58,59\">",
"     53,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in the demographics, clinical presentation, and gender distribution suggest that there are two key pathways to developing GBC in patients with cholelithiasis and anomalous pancreaticobiliary duct junction. The main mechanism involves cholelithiasis and resultant cholecystitis, and seems to be the driving force in most regions of the world where GBC is strongly associated with gallstone disease, female gender bias, and age over 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is hypothesized that chronic irritation of the gallbladder mucosa over a period of years may predispose to malignant transformation or act as a promoter for carcinogenic exposure or genetic predisposition. In keeping with this hypothesis, bile samples from patients in endemic areas are more mutagenic than those from patients from low incidence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/60\">",
"     60",
"    </a>",
"    ]. Despite these data, there is no conclusive evidence linking bile composition to GBC.",
"   </p>",
"   <p>",
"    A second mechanism involves anomalous pancreaticobiliary duct junction, which is associated with a relatively high proportion of cases of GBC in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/61\">",
"     61",
"    </a>",
"    ]. Cancers associated with this condition occur at a younger age, show less female gender bias, and have a lower incidence of associated cholelithiasis.",
"   </p>",
"   <p>",
"    There are also histologic and molecular differences in GBCs associated with an anomalous pancreaticobiliary duct junction and those associated with gallstones, providing further evidence that two distinct pathogenetic pathways are involved (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/8\">",
"     8",
"    </a>",
"    ]. GBCs arising in Japan in the setting of an anomalous pancreaticobiliary duct junction are characterized by K-ras mutations and relatively late onset of p53 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. By contrast, at least in Chilean patients with cholelithiasis and chronic cholecystitis, K-ras mutations are rare, while p53 mutations arise early during multistage pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most epithelial cancers are preceded by a series of histologic and molecular changers that evolve over a period of several years or decades. The paradigm in which stepwise accumulation of specific molecular abnormalities characterizes the evolution from premalignant change to invasive cancer is best established in colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to other GI tract adenocarcinomas, adenocarcinomas involving the gallbladder progress from dysplasia, to carcinoma in situ (CIS), and then to invasive cancer. The molecular changes that characterize these sequential changes are less well characterized than those in colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to colorectal cancer, gallbladder adenomas are rarely found in the context of dysplastic changes; a",
"    <span class=\"nowrap\">",
"     metaplasia-dysplasia/CIS/invasive",
"    </span>",
"    carcinoma sequence seems far more prevalent than an",
"    <span class=\"nowrap\">",
"     adenoma/carcinoma",
"    </span>",
"    sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/68\">",
"     68",
"    </a>",
"    ]. Further, incidentally identified gallbladder adenomas uncommonly harbor cancerous changes and seem to represent an entity with only a small clinical risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=see_link&amp;anchor=H11#H11\">",
"     \"Gallbladder polyps and cholesterolosis\", section on 'Adenomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are molecular differences between dysplastic lesions and adenomas which may account for underlying biologic differences. Mutations in beta-catenin (CTNNB1) are frequent in adenomas, but rare in",
"    <span class=\"nowrap\">",
"     dysplastic/carcinoma",
"    </span>",
"    lesions. As noted above, Kras mutations have been identified in dysplastic and hyperplastic lesions associated with anomalous pancreaticobiliary duct junction; this anatomic variant is associated with a significant risk for carcinoma, and these tumors consistently demonstrate K-ras mutations. The reciprocal relationship between CTNNB1 and K-ras mutations among adenomas and",
"    <span class=\"nowrap\">",
"     dysplasia/carcinomas,",
"    </span>",
"    the frequent association of dysplasia with invasive carcinoma, and the less common finding of adenoma in cancer specimens all suggest that gallbladder adenomas represent a distinct biologic process with a relatively low malignant potential, while K-ras mutated dysplastic lesions have a high malignant potential.",
"   </p>",
"   <p>",
"    Dysplastic changes can be found in the mucosa adjacent to over 90 percent of GBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/69\">",
"     69",
"    </a>",
"    ], and they are relatively frequent in routine cholecystectomy specimens. The entire sequence appears to take approximately 15 years. Symptomatic cholecystitis seldom appears before the age of 40, the median age for detecting dysplasia is 45 years of age, and for carcinoma in situ it is 55 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/70\">",
"     70",
"    </a>",
"    ]. Squamous metaplasia is a rare premalignant lesion found in association with invasive squamous cell GBC.",
"   </p>",
"   <p>",
"    By contrast, in both adults and children with an anomalous pancreaticobiliary duct junction, epithelial hyperplasia with a papillary or villous appearance is present in 39 to 61 percent of cases and is thought to represent a premalignant histologic change in the gallbladder mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/61,71,72\">",
"     61,71,72",
"    </a>",
"    ]. Hyperplasia then progresses to dysplasia, similar to the usual form of GBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GBC may present with one of four different clinical scenarios: malignancy suspected preoperatively because of symptoms, malignancy found incidentally on a radiologic examination such as a CT scan or ultrasound performed for another purpose, malignancy found intraoperatively at the time of cholecystectomy for presumed benign disease, and malignancy diagnosed incidentally on pathologic examination after a simple cholecystectomy. The last scenario is the most common mode of presentation of early stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43399?source=see_link\">",
"     \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with early invasive GBC are most often asymptomatic, or they have nonspecific symptoms that mimic or are due to cholelithiasis or cholecystitis. Before ultrasonography and CT became widely available, the preoperative diagnosis rate for GBC was only 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/73\">",
"     73",
"    </a>",
"    ]. However, with an appropriate index of suspicion and better imaging techniques, a preoperative diagnosis may be reached in 75 to 88 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/74\">",
"     74",
"    </a>",
"    ]. Early tumors as small as 5 mm can be recognized as a polypoid mass projecting into the gallbladder lumen, or as a focal thickening of the gallbladder wall [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/28,75\">",
"     28,75",
"    </a>",
"    ]. Even so, only about 50 percent of GBCs are recognized before operation in contemporary series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/15,76\">",
"     15,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among symptomatic patients, the most common complaint is pain, followed by anorexia, nausea, or vomiting. The symptoms of advanced GBC often differ from usual biliary colic and are more suggestive of malignant disease (eg, malaise, weight loss). Patients who present with a symptom complex suggestive of acute cholecystitis more often have earlier stage disease and a better long-term outcome than those who present otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with GBC may also present with obstructive jaundice, either from direct invasion of the biliary tree, or from metastatic disease to the region of the hepatoduodenal ligament. This diagnosis should be particularly suspected if a compression of the common hepatic duct by an impacted stone in the gallbladder neck is identified (ie, the Mirizzi syndrome). Invasion of tumor into the porta hepatis may also result in duodenal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of duodenal obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jaundice implies unresectability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=see_link\">",
"     \"Mirizzi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, patients present with extraabdominal metastases, hepatomegaly, a palpable mass, ascites, or paraneoplastic syndromes (eg, ectopic hormone secretion or acanthosis nigricans). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Acanthosis nigricans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since many patients are diagnosed intraoperatively, an important issue is the screening of patients with symptomatic biliary tract disease for the possibility of a coexisting GBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual diagnostic study for gallstone-related disease is ultrasonography (US). Many patients with an incidental GBC are found retrospectively to have had suspicious US findings (eg, a solitary or displaced stone, or an intraluminal or invasive mass) that were not recognized preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/77\">",
"     77",
"    </a>",
"    ]. Findings that are suggestive but not diagnostic of GBC include mural thickening or calcification, a mass protruding into the lumen, a fixed mass in the gallbladder, loss of the interface between the gallbladder and liver, or direct liver infiltration.",
"   </p>",
"   <p>",
"    Small polypoid lesions within the gallbladder may represent adenomas, papillomas, cholesterolosis, or carcinomas. Polyps over 1 cm in diameter are more likely to contain an invasive cancer than smaller ones [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/75,78,79\">",
"     75,78,79",
"    </a>",
"    ]. In one series, cancer was found in 23 and 0 percent of polyps larger than or smaller than 1 cm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/79\">",
"     79",
"    </a>",
"    ]. Thus, cholecystectomy should be strongly considered for patients with gallbladder polyps &gt;1 cm. Although fine needle aspiration biopsy may be useful to distinguish cholesterolosis from GBC, the distinction between an adenoma and a GBC is less accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=see_link\">",
"     \"Gallbladder polyps and cholesterolosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall accuracy of US for staging the local and distant extent of a suspected GBC is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/81\">",
"     81",
"    </a>",
"    ]. In one report of 26 patients, accuracy was only 38 percent, and the sensitivity for detection of liver infiltration or nodal metastases was only 50 percent each [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasonography (EUS) is more accurate for imaging the gallbladder than is extracorporeal US. It is useful both in the differential diagnosis of gallbladder polyps and in staging tumor extent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 194 patients with polypoid lesions &lt;20 mm who underwent both US and EUS, 58 had a cholecystectomy, either because of symptoms or suspicion of neoplasia by EUS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/82\">",
"       82",
"      </a>",
"      ]. Compared to transabdominal US, EUS more often correctly predicted the histologic diagnosis (97 versus 76 percent) (",
"      <a class=\"graphic graphic_table graphicRef52861 \" href=\"UTD.htm?3/27/3516\">",
"       table 2",
"      </a>",
"      ). In a second series, 89 patients with polyps &lt;20 mm underwent both EUS and US [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/83\">",
"       83",
"      </a>",
"      ]. The sensitivity, specificity, positive, and negative predictive values for the diagnosis of GBC were 92, 88, 76, and 97 percent for EUS, compared to 54, 54, 54, and 95 percent for US.",
"     </li>",
"     <li>",
"      EUS is a useful modality to assess the depth of tumor invasion into the wall of the gallbladder [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/84,85\">",
"       84,85",
"      </a>",
"      ] and for defining lymph node involvement in the porta hepatis or peripancreatic regions.",
"     </li>",
"     <li>",
"      EUS also can provide a means of obtaining bile for cytologic analysis, which has a sensitivity of 73 percent for the diagnosis of GBC [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/86\">",
"       86",
"      </a>",
"      ]. Furthermore, EUS-guided FNA is an accurate and safe tool in the evaluation of gallbladder masses [",
"      <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If available, we perform EUS on patients with gallbladder polyps or a thickened gallbladder wall, as well as those with jaundice, or a high serum bilirubin or alkaline phosphatase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CT and MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;On CT, GBC can appear as a polypoid mass protruding into the lumen or completely filling it, a focal or diffuse thickening of the gallbladder wall, or a mass in the gallbladder fossa with the gallbladder itself being indiscernible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/88\">",
"     88",
"    </a>",
"    ]; liver invasion, suspected nodal involvement, or distant metastases may be shown [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT is less helpful in distinguishing benign from malignant polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/90\">",
"     90",
"    </a>",
"    ]. In contrast, dynamic MRI and MR cholangiopancreatography (MRCP) can help to differentiate benign from malignant gallbladder lesions in equivocal cases and provide information as to disease extent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. MRI is particularly useful for visualizing invasion into the hepatoduodenal ligament, portal vein encasement, and lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cholangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiography, endoscopic retrograde cholangiopancreatography (ERCP), and percutaneous transhepatic cholangiopancreatography are of little use for patients suspected of having GBC since the gallbladder is not observed in most cases. These procedures may be helpful in planning the surgical procedure as they may indicate tumor growth in intrahepatic biliary ducts or in the common bile duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22340969\">",
"    <span class=\"h2\">",
"     PET and integrated PET/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with gallbladder cancer is unclear. Most (86 percent) gallbladder cancers are FDG-avid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], and PET scanning may help to distinguish between benign and malignant gallbladder wall thickening found on ultrasound, CT, or MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. However, while some data suggest that PET predicts residual disease in the local tumor bed in over 80 percent of patients who had a recent previous cholecystectomy and were found to have an incidental gallbladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], the temptation to use FDG-PET to determine the need for re-resection should be tempered by the frequent finding of increased FDG-PET activity in the local tumor bed as a common early postoperative change [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/93,94\">",
"     93,94",
"    </a>",
"    ] and the high rate of residual disease even in incidentally discovered T1 disease (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main utility for PET is in identifying otherwise radiographically occult advanced disease in order to avoid unnecessary surgery. In retrospective studies, preoperative PET scanning changed stage and treatment in approximately 17 to 23 percent of patients with an apparently localized, potentially resectable gallbladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/93,98,100\">",
"     93,98,100",
"    </a>",
"    ]. However, others document a low sensitivity for extrahepatic disease in this setting (50 percent), particularly for identifying peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data are insufficient to make conclusive statements about the clinical utility of PET or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the management of patients with gallbladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/101\">",
"     101",
"    </a>",
"    ]. Nevertheless, most institutions do not pursue a PET or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    prior to resection of a gallbladder cancer given the relative insensitivity for small peritoneal metastases, or prior to reresection following a prior cholecystectomy because of the difficulty in distinguishing between FDG-avid inflammation and FDG-avid cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are generally nondiagnostic; an elevated alkaline phosphatase or serum bilirubin may be related to bile duct obstruction. Serum tumor markers such as carcinoembryonic antigen (CEA) or CA 19-9 are often elevated, but not diagnostically useful because they lack specificity and sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7707725\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When radical surgery is being considered in a patient with documented or suspected gallbladder cancer, preoperative imaging is important to rule out metastatic or locally unresectable disease. The preoperative evaluation should include abdominal CT and MRCP.",
"   </p>",
"   <p>",
"    Although some institutions perform a PET scan in patients who appear otherwise to have potentially resectable disease, most do not, and guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    do not recommend PET or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    for patients with a mass on imaging, or an incidental finding of gallbladder cancer either at surgery or pathologic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=see_link&amp;anchor=H1159123350#H1159123350\">",
"     \"Surgical management of gallbladder cancer\", section on 'Preoperative imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic classification of primary neoplasms arising in the gallbladder is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76301 \" href=\"UTD.htm?8/26/8619\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/104\">",
"     104",
"    </a>",
"    ]. The majority (close to 90 percent) are adenocarcinomas, although other histologic types are occasionally found, including adenosquamous or squamous cell carcinoma, small cell neuroendocrine tumors , lymphoma, and sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/15,105,106\">",
"     15,105,106",
"    </a>",
"    ]. Grossly, GBC can appear infiltrative, nodular, papillary, or a combination of these morphologies. Papillary carcinomas, which can sometimes fill the entire gallbladder, have the most favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenocarcinomas originate as mucosal lesions, invading the gallbladder wall as they grow. The lack of a well-defined muscularis layer permits early vascular, lymphatic, and neural invasion. Tumors frequently extend outside of the gallbladder, invading adjacent organs, particularly the liver, as they grow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several staging systems have been used for GBC. Although the staging system developed by Nevin is still used, particularly in Europe, the TNM staging system of the American Joint Committee on Cancer (AJCC) is the preferred classification scheme in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nevin staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally described in 1976, the Nevin staging system for GBC includes five stages that are defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/107\">",
"     107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; Intramucosal only",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of mucosa and muscularis",
"     </li>",
"     <li>",
"      Stage III &mdash; Involvement of all three layers",
"     </li>",
"     <li>",
"      Stage IV &mdash; Involvement of all three layers and the cystic lymph node",
"     </li>",
"     <li>",
"      Stage V &mdash; Involvement of liver by direct extension or metastases to any other organ",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     TNM staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Joint Committee on Cancer (AJCC) TNM staging classification of GBC is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70554 \" href=\"UTD.htm?6/41/6813\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/108\">",
"     108",
"    </a>",
"    ]. The most recent 2010 staging system differs from the 2002 version in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors of the cystic duct are included in this classification scheme",
"     </li>",
"     <li>",
"      The N classification now distinguishes regional hilar nodes (those adjacent to the cystic duct, common bile duct, hepatic artery, and portal vein; N1 nodes) from other lymph nodes that are staged as N2 but considered to represent distant metastatic disease (celiac, along the superior mesenteric artery, periaortic, pericaval).",
"     </li>",
"     <li>",
"      The stage groupings have been realigned to better correlate with resectability and prognosis",
"     </li>",
"     <li>",
"      T4 (locally unresectable) tumors were moved from stage III to IVA disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes in the classification of gallbladder cancer have improved the prognostic stratification of the staging system. Observed survival rates from a series of 10,705 cases of GBC collected between 1989 and 1996 in the National Cancer Database [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/109\">",
"     109",
"    </a>",
"    ] and stratified according to stage at diagnosis (using the 2010 criteria) are provided in the table (",
"    <a class=\"graphic graphic_figure graphicRef80678 \" href=\"UTD.htm?26/59/27568\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/109\">",
"     109",
"    </a>",
"    ]. However, they have obvious implications for interpretation and comparison of outcomes from trials and retrospective series that use the 2002 versus the 2010 staging criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Distribution of disease stage at presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary T stage distribution in a contemporary series of 439 cases of incidentally found GBC from a German registry, stratified according to the type of surgical procedure, is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef71493 \" href=\"UTD.htm?26/44/27339\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/110\">",
"     110",
"    </a>",
"    ]. Positive lymph nodes were found in 21 and 44 percent of the reresected patients with T2 and T3 tumors.",
"   </p>",
"   <p>",
"    The mode of presentation impacts on the stage distribution of GBC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/15,76,110\">",
"     15,76,110",
"    </a>",
"    ], as illustrated by data from Memorial Sloan Kettering [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/15\">",
"     15",
"    </a>",
"    ]. In a large series of 435 gallbladder cancers seen at over a ten-year period, 159 (37 percent) had stage IV disease at diagnosis, and another 70 (16 percent) had locally advanced nonmetastatic but unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/46/15082/abstract/15\">",
"     15",
"    </a>",
"    ]. Of the remaining 206 patients, all of whose tumors had been discovered incidentally, 136 had no evidence of metastatic disease on radiologic examination and were deemed candidates for reexploration and possible radical reexcision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/31/4595?source=see_link\">",
"       \"Patient information: Gallbladder cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20727141\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallbladder cancer (GBC) is an uncommon but highly fatal malignancy. Worldwide, there is a prominent geographic variability in GBC incidence that correlates with the prevalence of cholelithiasis. Incidence steadily increases with age, women are affected two to six times more often than men, and GBC is more common in Caucasians than in blacks. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority (close to 90 percent) are adenocarcinomas, although other histologic types are occasionally found, including adenosquamous or squamous cell carcinoma, small cell neuroendocrine tumors, lymphoma, and sarcoma. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Histology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several risk factors have been identified, many of which share a common characteristic of chronic gallbladder inflammation: gallstone disease, gallbladder polyps and congenital biliary cysts, anomalous pancreaticobiliary junction, and chronic infection. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Similar to other gastrointestinal tract adenocarcinomas, adenocarcinomas involving the gallbladder progress from dysplasia, to carcinoma in situ (CIS), and then to invasive cancer. The molecular changes that characterize these sequential changes are less well characterized than those in colorectal cancer. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with early invasive GBC are most often asymptomatic, or they have nonspecific symptoms that mimic or are due to cholelithiasis or cholecystitis. Malignancy diagnosed incidentally on pathologic examination after a simple cholecystectomy is the most common mode of presentation of early stage disease. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Endoscopic ultrasonography (EUS) is more accurate for imaging the gallbladder than is extracorporeal ultrasound. It is useful both in the differential diagnosis of gallbladder polyps and in staging tumor extent. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Endoscopic ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    On CT scan, GBC can appear as a polypoid mass protruding into the lumen or completely filling it, a focal or diffuse thickening of the gallbladder wall, or a mass in the gallbladder fossa with the gallbladder itself being indiscernible. Dynamic MRI and MR cholangiopancreatography (MRCP) can help to differentiate benign from malignant gallbladder lesions in equivocal cases and provide information as to disease extent. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'CT and MRI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cholangiography is of little use for patients suspected of having GBC since the gallbladder is not observed in most cases. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Cholangiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several staging systems have been used for GBC. Although the staging system developed by Nevin is still used, particularly in Europe, the TNM staging system of the American Joint Committee on Cancer (AJCC) is the preferred classification scheme in the United States. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Staging'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/1\">",
"      Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/2\">",
"      Hamrick RE Jr, Liner FJ, Hastings PR, Cohn I Jr. Primary carcinoma of the gallbladder. Ann Surg 1982; 195:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/3\">",
"      Yamaguchi K, Chijiiwa K, Ichimiya H, et al. Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch Surg 1996; 131:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/4\">",
"      A prospective analysis of 1518 laparoscopic cholecystectomies. The Southern Surgeons Club. N Engl J Med 1991; 324:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/5\">",
"      Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 1995; 76:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/6\">",
"      Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006; 118:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/7\">",
"      Lazcano-Ponce EC, Miquel JF, Mu&ntilde;oz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/8\">",
"      Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004; 4:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/9\">",
"      Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998; 115:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/10\">",
"      Serra I, Calvo A, B&aacute;ez S, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 1996; 78:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/11\">",
"      Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009; 20:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/12\">",
"      Kiran RP, Pokala N, Dudrick SJ. Incidence pattern and survival for gallbladder cancer over three decades--an analysis of 10301 patients. Ann Surg Oncol 2007; 14:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/13\">",
"      Yang JD, Kim B, Sanderson SO, et al. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol 2012; 107:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/14\">",
"      Diehl AK. Epidemiology of gallbladder cancer: a synthesis of recent data. J Natl Cancer Inst 1980; 65:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/15\">",
"      Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008; 98:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/16\">",
"      Konstantinidis IT, Deshpande V, Genevay M, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg 2009; 144:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/17\">",
"      Scott TE, Carroll M, Cogliano FD, et al. A case-control assessment of risk factors for gallbladder carcinoma. Dig Dis Sci 1999; 44:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/18\">",
"      Caygill CP, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 1994; 343:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/19\">",
"      Hsing AW, Gao YT, Han TQ, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007; 97:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/20\">",
"      Maringhini A, Moreau JA, Melton LJ 3rd, et al. Gallstones, gallbladder cancer, and other gastrointestinal malignancies. An epidemiologic study in Rochester, Minnesota. Ann Intern Med 1987; 107:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/21\">",
"      Paraskevopoulos JA, Dennison AR, Ross B, Johnson AG. Primary carcinoma of the gallbladder: a 10-year experience. Ann R Coll Surg Engl 1992; 74:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/22\">",
"      Zatonski WA, Lowenfels AB, Boyle P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997; 89:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/23\">",
"      Ghadirian P, Simard A, Baillargeon J. A population-based case-control study of cancer of the bile ducts and gallbladder in Quebec, Canada. Rev Epidemiol Sante Publique 1993; 41:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/24\">",
"      Chow WH, Johansen C, Gridley G, et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999; 79:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/25\">",
"      Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/26\">",
"      GLENN F, HAYS DM. The scope of radical surgery in the treatment of malignant tumors of the extrahepatic biliary tract. Surg Gynecol Obstet 1954; 99:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/27\">",
"      Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999; 30:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/28\">",
"      Okamoto M, Okamoto H, Kitahara F, et al. Ultrasonographic evidence of association of polyps and stones with gallbladder cancer. Am J Gastroenterol 1999; 94:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/29\">",
"      Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000; 95:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/30\">",
"      Shukla VK, Singh H, Pandey M, et al. Carcinoma of the gallbladder--is it a sequel of typhoid? Dig Dis Sci 2000; 45:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/31\">",
"      Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. Eur J Cancer Prev 1997; 6:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/32\">",
"      Kobayashi T, Harada K, Miwa K, Nakanuma Y. Helicobacter genus DNA fragments are commonly detectable in bile from patients with extrahepatic biliary diseases and associated with their pathogenesis. Dig Dis Sci 2005; 50:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/33\">",
"      Murata H, Tsuji S, Tsujii M, et al. Helicobacter bilis infection in biliary tract cancer. Aliment Pharmacol Ther 2004; 20 Suppl 1:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/34\">",
"      Fukuda K, Kuroki T, Tajima Y, et al. Comparative analysis of Helicobacter DNAs and biliary pathology in patients with and without hepatobiliary cancer. Carcinogenesis 2002; 23:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/35\">",
"      Matsukura N, Yokomuro S, Yamada S, et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res 2002; 93:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/36\">",
"      Metz DC. Helicobacter colonization of the biliary tree: commensal, pathogen, or spurious finding? Am J Gastroenterol 1998; 93:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/37\">",
"      Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg 1983; 118:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/38\">",
"      Song HK, Kim MH, Myung SJ, et al. Choledochal cyst associated the with anomalous union of pancreaticobiliary duct (AUPBD) has a more grave clinical course than choledochal cyst alone. Korean J Intern Med 1999; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/39\">",
"      Chijiiwa K, Kimura H, Tanaka M. Malignant potential of the gallbladder in patients with anomalous pancreaticobiliary ductal junction. The difference in risk between patients with and without choledochal cyst. Int Surg 1995; 80:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/40\">",
"      Hasumi A, Matsui H, Sugioka A, et al. Precancerous conditions of biliary tract cancer in patients with pancreaticobiliary maljunction: reappraisal of nationwide survey in Japan. J Hepatobiliary Pancreat Surg 2000; 7:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/41\">",
"      Hu B, Gong B, Zhou DY. Association of anomalous pancreaticobiliary ductal junction with gallbladder carcinoma in Chinese patients: an ERCP study. Gastrointest Endosc 2003; 57:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/42\">",
"      Elnemr A, Ohta T, Kayahara M, et al. Anomalous pancreaticobiliary ductal junction without bile duct dilatation in gallbladder cancer. Hepatogastroenterology 2001; 48:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/43\">",
"      Sugiyama M, Abe N, Tokuhara M, et al. Pancreatic carcinoma associated with anomalous pancreaticobiliary junction. Hepatogastroenterology 2001; 48:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/44\">",
"      Sugiyama M, Atomi Y. Anomalous pancreaticobiliary junction without congenital choledochal cyst. Br J Surg 1998; 85:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/45\">",
"      Funabiki T, Matsubara T, Ochiai M, et al. Surgical strategy for patients with pancreaticobiliary maljunction without choledocal dilatation. Keio J Med 1997; 46:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/46\">",
"      Brod&eacute;n G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand Suppl 1980; 500:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/47\">",
"      Ellis EF, Gordon PR, Gottlieb LS. Oral contraceptives and cholangiocarcinoma. Lancet 1978; 1:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/48\">",
"      Lowenfels AB, Norman J. Isoniazid and bile duct cancer. JAMA 1978; 240:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/49\">",
"      Milne R, Vessey M. The association of oral contraception with kidney cancer, colon cancer, gallbladder cancer (including extrahepatic bile duct cancer) and pituitary tumours. Contraception 1991; 43:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/50\">",
"      Combined oral contraceptives and gallbladder cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989; 18:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/51\">",
"      Pandey M, Shukla VK. Lifestyle, parity, menstrual and reproductive factors and risk of gallbladder cancer. Eur J Cancer Prev 2003; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/52\">",
"      Darby SC, Whitley E, Howe GR, et al. Radon and cancers other than lung cancer in underground miners: a collaborative analysis of 11 studies. J Natl Cancer Inst 1995; 87:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/53\">",
"      Grainge MJ, West J, Solaymani-Dodaran M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009; 100:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/54\">",
"      Yagyu K, Kikuchi S, Obata Y, et al. Cigarette smoking, alcohol drinking and the risk of gallbladder cancer death: a prospective cohort study in Japan. Int J Cancer 2008; 122:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/55\">",
"      Engeland A, Tretli S, Austad G, Bj&oslash;rge T. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control 2005; 16:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/56\">",
"      Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/57\">",
"      Hsing AW, Sakoda LC, Rashid A, et al. Body size and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2008; 99:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/58\">",
"      Shebl FM, Andreotti G, Rashid A, et al. Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China. Br J Cancer 2010; 103:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/59\">",
"      Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/60\">",
"      Mano H, Roa I, Araya JC, et al. Comparison of mutagenic activity of bile between Chilean and Japanese female patients having cholelithiasis. Mutat Res 1996; 371:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/61\">",
"      Sasatomi E, Tokunaga O, Miyazaki K. Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg 2000; 7:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/62\">",
"      Hidaka E, Yanagisawa A, Seki M, et al. High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater. Cancer Res 2000; 60:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/63\">",
"      Hanada K, Tsuchida A, Iwao T, et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999; 94:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/64\">",
"      Masuhara S, Kasuya K, Aoki T, et al. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 2000; 7:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/65\">",
"      Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/66\">",
"      Wistuba II, Sugio K, Hung J, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/67\">",
"      Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 1996; 27:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/68\">",
"      Roa I, de Aretxabala X, Araya JC, Roa J. Preneoplastic lesions in gallbladder cancer. J Surg Oncol 2006; 93:615.",
"     </a>",
"    </li>",
"    <li>",
"     Albores-Saavedra J, Hensen DE. Tumors of gallbladder and extrahepatic bile ducts. Fascicle 23, 3rd edition; Armed Forces Institute Pathology, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/70\">",
"      Roa I, Araya JC, Villaseca M, et al. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology 1996; 111:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/71\">",
"      Tanno S, Obara T, Fujii T, et al. Epithelial hyperplasia of the gallbladder in children with anomalous pancreaticobiliary ductal union. Hepatogastroenterology 1999; 46:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/72\">",
"      Hanada K, Itoh M, Fujii K, et al. Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1996; 91:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/73\">",
"      Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978; 147:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/74\">",
"      Chijiiwa K, Sumiyoshi K, Nakayama F. Impact of recent advances in hepatobiliary imaging techniques on the preoperative diagnosis of carcinoma of the gallbladder. World J Surg 1991; 15:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/75\">",
"      Kubota K, Bandai Y, Noie T, et al. How should polypoid lesions of the gallbladder be treated in the era of laparoscopic cholecystectomy? Surgery 1995; 117:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/76\">",
"      L&ouml;he F, Meimarakis G, Schauer C, et al. The time of diagnosis impacts surgical management but not the outcome of patients with gallbladder carcinoma. Eur J Med Res 2009; 14:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/77\">",
"      Wibbenmeyer LA, Sharafuddin MJ, Wolverson MK, et al. Sonographic diagnosis of unsuspected gallbladder cancer: imaging findings in comparison with benign gallbladder conditions. AJR Am J Roentgenol 1995; 165:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/78\">",
"      Edelman DS. Carcinoma of a gallbladder polyp: treated by laparoscopic laser cholecystectomy. Surg Laparosc Endosc 1993; 3:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/79\">",
"      Toda K, Souda S, Yoshikawa Y, et al. Significance of laparoscopic excisional biopsy for polypoid lesions of the gallbladder. Surg Laparosc Endosc 1995; 5:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/80\">",
"      Wu SS, Lin KC, Soon MS, Yeh KT. Ultrasound-guided percutaneous transhepatic fine needle aspiration cytology study of gallbladder polypoid lesions. Am J Gastroenterol 1996; 91:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/81\">",
"      Pandey M, Sood BP, Shukla RC, et al. Carcinoma of the gallbladder: role of sonography in diagnosis and staging. J Clin Ultrasound 2000; 28:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/82\">",
"      Sugiyama M, Atomi Y, Yamato T. Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions: analysis in surgical and follow up series. Gut 2000; 46:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/83\">",
"      Azuma T, Yoshikawa T, Araida T, Takasaki K. Differential diagnosis of polypoid lesions of the gallbladder by endoscopic ultrasonography. Am J Surg 2001; 181:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/84\">",
"      Fujita N, Noda Y, Kobayashi G, et al. Diagnosis of the depth of invasion of gallbladder carcinoma by EUS. Gastrointest Endosc 1999; 50:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/85\">",
"      Sadamoto Y, Kubo H, Harada N, et al. Preoperative diagnosis and staging of gallbladder carcinoma by EUS. Gastrointest Endosc 2003; 58:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/86\">",
"      Mohandas KM, Swaroop VS, Gullar SU, et al. Diagnosis of malignant obstructive jaundice by bile cytology: results improved by dilating the bile duct strictures. Gastrointest Endosc 1994; 40:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/87\">",
"      Wu LM, Jiang XX, Gu HY, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy in the evaluation of bile duct strictures and gallbladder masses: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2011; 23:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/88\">",
"      Kumar A, Aggarwal S. Carcinoma of the gallbladder: CT findings in 50 cases. Abdom Imaging 1994; 19:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/89\">",
"      Ohtani T, Shirai Y, Tsukada K, et al. Spread of gallbladder carcinoma: CT evaluation with pathologic correlation. Abdom Imaging 1996; 21:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/90\">",
"      Furukawa H, Kosuge T, Shimada K, et al. Small polypoid lesions of the gallbladder: differential diagnosis and surgical indications by helical computed tomography. Arch Surg 1998; 133:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/91\">",
"      Yoshimitsu K, Honda H, Kaneko K, et al. Dynamic MRI of the gallbladder lesions: differentiation of benign from malignant. J Magn Reson Imaging 1997; 7:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/92\">",
"      Schwartz LH, Black J, Fong Y, et al. Gallbladder carcinoma: findings at MR imaging with MR cholangiopancreatography. J Comput Assist Tomogr 2002; 26:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/93\">",
"      Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/94\">",
"      Anderson CD, Rice MH, Pinson CW, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/95\">",
"      Oe A, Kawabe J, Torii K, et al. Distinguishing benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med 2006; 20:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/96\">",
"      Koh T, Taniguchi H, Yamaguchi A, et al. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol 2003; 84:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/97\">",
"      Rodr&iacute;guez-Fern&aacute;ndez A, G&oacute;mez-R&iacute;o M, Llamas-Elvira JM, et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg 2004; 188:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/98\">",
"      Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/99\">",
"      Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg 2007; 11:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/100\">",
"      Lee SW, Kim HJ, Park JH, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010; 45:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/101\">",
"      Sacks A, Peller PJ, Surasi DS, et al. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol 2011; 197:W260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/102\">",
"      Strom BL, Maislin G, West SL, et al. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer 1990; 45:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/103\">",
"      Ritts RE Jr, Nagorney DM, Jacobsen DJ, et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994; 9:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/104\">",
"      Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/105\">",
"      Mitropoulos FA, Angelopoulou MK, Siakantaris MP, et al. Primary non-Hodgkin's lymphoma of the gall bladder. Leuk Lymphoma 2000; 40:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/106\">",
"      Kim WS, Jang KT, Choi DW, et al. Clinicopathologic analysis of adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol 2011; 103:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/107\">",
"      Nevin JE, Moran TJ, Kay S, King R. Carcinoma of the gallbladder: staging, treatment, and prognosis. Cancer 1976; 37:141.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.211.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/109\">",
"      Fong Y, Wagman L, Gonen M, et al. Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. Ann Surg 2006; 243:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/46/15082/abstract/110\">",
"      Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg 2008; 247:104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2491 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-AF412BCB0E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15082=[""].join("\n");
var outline_f14_46_15082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20727141\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gallstone disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Porcelain gallbladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gallbladder polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Salmonella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Helicobacter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Congenital biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Abnormal pancreaticobiliary duct junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carcinogen exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H588275136\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CT and MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cholangiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22340969\">",
"      PET and integrated PET/CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7707725\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nevin staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TNM staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Distribution of disease stage at presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20727141\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2491|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/59/27568\" title=\"figure 1\">",
"      Survival rates for gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/17/40219\" title=\"table 1\">",
"      Frequency gallbladder polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/27/3516\" title=\"table 2\">",
"      EUS gallbladder polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/26/8619\" title=\"table 3\">",
"      Histology gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/41/6813\" title=\"table 4\">",
"      TNM staging gallbladder CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/44/27339\" title=\"table 5\">",
"      Stage distribution for gallbladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43399?source=related_link\">",
"      Adjuvant treatment for localized, potentially resectable gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=related_link\">",
"      Biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=related_link\">",
"      Pathogenesis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/31/4595?source=related_link\">",
"      Patient information: Gallbladder cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39668?source=related_link\">",
"      Porcelain gallbladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=related_link\">",
"      Surgical management of gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33977?source=related_link\">",
"      Treatment of advanced, unresectable gallbladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_46_15083="Mechs thyroid autoimm";
var content_f14_46_15083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mechanisms of thyroid autoimmunity with an emphasis on Hashimoto's thyroiditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mediating mechanisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular mimicry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bystander activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid cell HLA antigen expression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Precipitating causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic susceptibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex steroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy and fetal microchimerism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15083=[""].join("\n");
var outline_f14_46_15083=null;
var title_f14_46_15084="Calculate compatible blood";
var content_f14_46_15084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Calculating availability of blood in a patient with multiple alloantibodies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        Transfusion candidates with known antibodies require blood negative for that antigen. The ease of finding such blood is inversely proportional to that antigen's frequency in the donor population (ie, the less common the antigen, the easier it will be to find compatible [ie, entigen negative] blood).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        In addition, the blood needs to be matched for the patient's ABO and Rh(D) type, since A, B, and Rh(D) are potent antigens.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Blood group",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Frequency of antigen POSITIVITY (white population)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        O",
"       </td>",
"       <td>",
"        45 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A",
"       </td>",
"       <td>",
"        40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B",
"       </td>",
"       <td>",
"        11 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AB",
"       </td>",
"       <td>",
"        4 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Blood group",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Frequency of antigen NEGATIVITY (white population)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rh (D)",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        K",
"       </td>",
"       <td>",
"        91 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jk(b)",
"       </td>",
"       <td>",
"        28 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fy(a)",
"       </td>",
"       <td>",
"        37 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        To estimate the availability of blood, one multiplies the percentage of antigen-appropriate blood in the population for each of the antigens involved. In the example given in the text for a patient with Type O Rh negative blood, with anti-K, anti-Jk(b), and anti Fy(a), the percent of blood available is calculated as shown below:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        O positive (0.45) x Rh negative (0.15) x K negative (0.91) x Jk(b) negative (0.28) x Fy(a) negative (0.37) = 0.006. Thus, six out of one thousand randomly collected units should be compatible.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15084=[""].join("\n");
var outline_f14_46_15084=null;
var title_f14_46_15085="Knock-knees DDx";
var content_f14_46_15085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of knock-knees in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Possible clues to the diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physiologic valgus",
"      </td>",
"      <td>",
"       Age 2 to 5 years; symmetric deformities; normal stature; lack of symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pathologic valgus",
"      </td>",
"      <td>",
"       Short stature; intermalleolar distance of &gt;8 cm with the patellas facing forward and the femoral condyles touching",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       Posttraumatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Proximal tibial fracture (Cozen fracture)",
"      </td>",
"      <td class=\"sublist_other\">",
"       History of proximal tibial fracture at age &lt;10 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Distal femoral physeal fracture",
"      </td>",
"      <td class=\"sublist_other\">",
"       History of fracture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       Systemic/metabolic conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Mucopolysaccharidosis type IV (Morquio syndrome) (OMIM #25300 and 253010)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Coarse facies, short stature, stiff joints, corneal opacities, lumbar kyphosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Renal osteodystrophy",
"      </td>",
"      <td class=\"sublist_other\">",
"       Short stature, pallor, polydipsia, polyuria, abnormal BUN/creatinine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Rickets (with onset during physiologic valgus: 2 to 4 years of age)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Decreased serum calcium or phosphorus, increased alkaline phosphatase; widened physes and flared metaphyses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Skeletal dysplasia",
"      </td>",
"      <td>",
"       Characteristic clinical and radiographic features vary according to the dysplasia. Some examples are provided below.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Chondroectodermal dysplasia (Ellis-van Creveld syndrome) (OMIM #225500)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Autosomal recessive inheritance; short stature; short limbs; dysplastic nails and teeth; cardiac defects; polydactyly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Spondyloepiphyseal dysplasia tarda (OMIM #313400)",
"      </td>",
"      <td class=\"sublist_other\">",
"       X-linked recessive inheritance; short stature with onset between 5 and 10 years; short trunk; corneal opacities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Pseudoachondroplasia (OMIM #177170); associated with bow-legs in some patients",
"      </td>",
"      <td class=\"sublist_other\">",
"       Autosomal dominant inheritance; short-limb dwarfism with onset by 2 years; joint laxity; vertebral anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Multiple epiphyseal dysplasia syndrome (OMIM #132400)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Autosomal dominant inheritance; mild short-limb dwarfism; brachydactyly; small irregular epiphyses on radiographs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       Neoplasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Multiple hereditary exostoses (OMIM #133700 and 133701)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Autosomal dominant inheritance; protruberances at ends of long bones; exostoses in juxtaepiphyseal regions of long bones",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Focal fibrocartilaginous dysplasia of distal femoral metaphysis",
"      </td>",
"      <td class=\"sublist_other\">",
"       Progressive, unilateral deformity; radiolucent, well-circumscribed lesion, often with rim of reactive bone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       Other conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Iliotibial band tightness (due to paralytic conditions, such as myelodysplasia, spastic diplegia, or spinal cord injury)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Abnormal Ober test (see text for details)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Arthritis of the knee (rheumatoid, hemophilia)",
"      </td>",
"      <td class=\"sublist_other\">",
"       History of joint swelling, warmth",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BUN: blood urea nitrogen; OMIM: Online Mendelian Inheritance in Man.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.",
"      <br>",
"       2. The knee and leg. In:&nbsp;Tachdjian MO. Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management. Appleton &amp; Lange, Stamford, CT 1997. p.87.",
"       <br>",
"        3. OMIM Online Mendelian Inheritance in Man (www.ncbi.nlm.nih.gov/omim/).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15085=[""].join("\n");
var outline_f14_46_15085=null;
var title_f14_46_15086="ACC AHA choice imaging CHD diagnosis able to exercise";
var content_f14_46_15086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52995%7ECARD%2F74428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52995%7ECARD%2F74428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate pretest probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression at rest",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Exercise myocardial perfusion imaging or exercise echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Adenosine or dipyridamole myocardial perfusion imaging in patients with an intermediate pretest probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Dobutamine stress echocardiography in patients with an intermediate pretest probability of CAD and left bundle branch block.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging and exercise echocardiography in patients with a low or high probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or high probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate probability of CAD who have one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Digoxin use with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. LVH with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Exercise myocardial perfusion imaging, exercise echocardiography, adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography as the initial stress test in a patient with a normal rest ECG who is not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Exercise in patients with left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise should be performed in the following manner:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients who do not have left bundle branch block or an electronically paced ventricular rhythm but have either an abnormal ECG or are taking digoxin, exercise myocardial perfusion imaging (MPI) or exercise echocardiography to identify the extent, severity, and location of ischemia.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients with left bundle branch block or an electronically paced ventricular rhythm, dipyridamole or adenosine MPI.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Among patients with left bundle branch block, dobutamine stress echocardiography.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; When assessing the functional significance of coronary lesions, exercise MPI or exercise echocardiography.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise echocardiography in the presence of left bundle branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise, dipyridamole, or adenosis MPI or exercise or dobutamine echocardiography in patients who have a normal rest ECG and are not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that cardiac stress imaging as the initial test for risk stratification of patients with chronic stable angina who are able to exercise is not useful in in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Exercise MPI in the presence of left bundle branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Severe comorbidity that is likely to limit life expectation or prevent revascularization.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher, LA, Beckman, JA, Brown, KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons, RJ, Abrams, J, Chatterjee, K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149. Copyright 2003 by the American College of Cardiology and American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15086=[""].join("\n");
var outline_f14_46_15086=null;
var title_f14_46_15087="Cobb angle";
var content_f14_46_15087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cobb angle measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Cobb angle (arrow) is formed by the intersection of a line parallel to the superior end plate of the most cephalad vertebra in a particular curve, with the line parallel to the inferior endplate of the most caudad vertebra of the curve. The intersection of these lines may occur outside the border of the actual film. Therefore, by convention, perpendiculars to the parallels are drawn, and the angle between their intersection is measured. The Cobb angle in the above radiograph is 63&deg;. By orthopaedic convention scoliosis images are viewed as if looking from the patient&rsquo;s back. The left side of the image is the left side of the patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_46_15087=[""].join("\n");
var outline_f14_46_15087=null;
